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ABSTRACT

COMPARISON OF POSITIVE SCREENING AND
CONFIRMATORY RESULTS FROM FEDERALLY
MANDATED DRUG TESTING OF URINE.
Mary M. Stuck
Old Dominion University, 1996
Director: Professor A. James English

The purpose of this study was to analyze the accuracy of FDA approved immunoassays
for the detection of drug positive urine samples.
Federal civilian employees are tested under the strict protocol of the Department o f
Health and Human Services mandatory guidelines for federal workplace drug testing
programs. The guidelines provide for a two instrument testing protocol for the analysis of
urine samples. The first is an FDA approved immunoassay. Samples which test positive
on this screening immunoassay are then submitted for confirmatory testing with the "gold
standard" gas chromatography/mass spectrometry.
Agency monthly drug testing summaries, required under the DHHS guidelines were
sought from the six largest federal agencies which performed drug testing on its civilian
employees in 1993 and 1994. These agencies were: Department of Air Force, Army,
Justice, Navy, Transportation and Veterans Affairs. This study covered more than half
o f the federal civilians tested during 1993 and 1994.
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Calculations were made o f the positive predictive value (PPV) of the screening test,
false presumptive positives and confirmed positive rates for each agency and
immunoassay. Positive predictive values are defined as the probability that the specific
immunoassay screen accurately predicts true lab positive urine samples.
The study concluded that GC/MS confirmation is scientifically necessary to ensure
accurate results. Failure to submit samples for GC/MS testing would result in 200-370
false positives annually among federal civilian employees. Those employees would then be
subject to disciplinary actions, including removal.
There were differences among immunoassays tested. The screening tests
accurately identified positive marijuana samples in 98.7% o f the cases. Similarly
opiates testing was the most problematic, positive predictive values approached 72%.
Amphetamine/methamphetamines immunoassays detected a weak 77% o f lab positive
urine samples. Comparisons among immunoassays utilized by federal
agencies drug testing laboratories found the best overall positive predictive values for
radioimmunoassay (RIA) at 90.8%, followed by Enzyme Multiplied Immunoassay
EMIT (88.8%), and lastly KIMs at 82.0%. Surprisingly KIMs showed weaknesses for the
detection o f phencyclidine (PCP).
The study concluded that while there are areas where federal drug testing costs may be
reduced (such as limiting the testing o f phencyclidine and choosing the most accurate
immunoassays), confirmation of positive screens by GC/MS is critical to ensure the
integrity o f federal drugtesting programs and should be used by private industry.
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Chapter I
INTRODUCTION
In 1986 President Reagan signed Executive Order 12564 which established a federal
drug free workplace program. It required the head of each executive branch agency to
establish a random testing program o f civilian employees in sensitive positions and a
voluntary drug testing program. The order also authorized agency urine testing when
there is a reasonable suspicion that an employee uses illegal drugs; in an examination
authorized by the agency following an unsafe practice or accident; as part of or to follow
up counseling or rehabilitation for illegal drug use; and when an individual applies for
employment with the agency. The Executive Order required the Department o f Health
and Human Services (DHHS) to promulgate standards on how drug testing would be
conducted.
Legal scholars such as Schroeder (1990), contend that federal initiatives such as
President Reagan's Executive Order and Public Law 100-71 which govern the scope of
federal drug testing, (and by extension the mandatory guidelines promulgated by DHHS)
have been the driving force for employment drug testing in this country. There is also little
doubt that drug testing methodology and drug testing itself have undergone a major
metamorphosis since its infancy with the military in the I970's (MacDonald, Wells and
Fry, 1993).

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

2

With the advent o f E .0 .12564, a remarkable decade ensued- numerous lawsuits were
filed which not only challenged the Constitutionality of drug testing under the 4th and 14th
Amendments (see NTEU v VonRaab. 109 S.Ct.1384, and Skinner v Railway Labor
Executives Assn 109 S.Ct. 1402), but also posed serious allegations o f inaccurate and
imprecise drug testing, citing the 5th Amendment right to due process.
Those concerns were particularly well founded. In the year preceding the issuance of
EO 12564 the Center for Disease Control (CDC) published the results of a blind study it
had conducted with the National Institute o f Drug Abuse (NIDA).
The CDC reported that each of the 13 drug screening laboratories it tested had
reported multiple false positive and false negative results on blind samples, although they
performed well on open proficiency samples. The labs reported unacceptable results for
amphetamines in 100% o f the cases, 91% were unacceptable for cocaine, etc. (Hansen,
Caudill and Boone, 1985).
In light of studies such as those conducted by the CDC, professional organizations
were very concerned about early drug testing practices. Accurate and reliable test results
were needed to forestall potential legal liability. The American Society o f Clinical
Chemistry spearheaded a consensus that the "gold standard" o f testing required both a
screening test and a gas chromatography/mass spectrometry confirmation (Substance
Abuse testing committee [SATC], 1988).
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Mandatory guidelines for federal testing
NEDA scientists and forensic toxicologists worked intensely to fulfill Reagan's mandate
under EO 12564 and to define a practical laboratory program that would permit testing o f
urine for the five commonly used illicit drugs and their metabolites (marijuana, cocaine,
amphetamines, opiates and phencyclidine) with a minimum o f error and maximum of
protection for employees (Under the Influence, 1994).
The result o f their work was first published as the "mandatory guidelines for federal
workplace drug testing programs" in April 1988 (DHHS, 1988). Just three months later a
national certification program was implemented by NEDA.
The guidelines contain a number o f safeguards, not the least o f which is a mandatory
certification program for all laboratories conducting urine testing o f federal civilian
employees. The guidelines include urine collection procedures, chain o f custody
provisions, strict quality control requirements, use of blind performance test specimens, a
two step testing procedure and verification o f all samples by a medical review officer.
Specifically, the testing protocol includes screening by a FDA approved immunoassay and
confirmation o f all specimens which screen positive by gas chromatography/mass
spectrometry (GC/MS).
In the nearly ten years which have elapsed since the issuance o f the federal
drug free workplace program drug testing has improved dramatically. Recent proficiency
results are a far cry from the "Crisis in drug testing" which the CDC reported in 1985
(Hansen et al, 1985).
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In fact with the possible exception of the 1990 study conducted by Knight, Freedman,
Puskas, Martel and O'Donnell, where they found 2% false positives and 20% false
negatives among certified laboratories, NIDA certified laboratories have consistently
scored above 95% on blind studies. (Frings, 1987; Dyszel,1993; Drug testing methods,
1990).
Laboratories certified by DHHS (or more specifically the National Institute o f Drug
Abuse branch o f DHHS which was renamed SAMHAS in 1994), have had remarkable
success.
Fay points out in his 1991 book on drug testing, certification by HHS "has come
to be regarded by the courts as a standard forjudging the accuracy and reliability o f
employer drug-testing activities." It was not until 1990 that a laboratory certified under
the guidelines had their certification revoked or suspended, when NIDA decertified three
laboratories for false positive results for methamphetamines.
Although notified by the Assistant Surgeon General at the Bureau of Prisons (BP) in
July 1989 that BP had erroneously disciplined an employee for using an illegal
methamphetamine caused by the legal form o f methampetamine found in an over-the
counter drug, (GAO, GAO/GGD-91-25, 1991), DHHS failed to alert federal agencies and
laboratories of the problem. It resurfaced in 1990 when three laboratories certifications
were suspended because of a similar problem excessive ephedrine or pseudo ephedrine in
over the counter medications gave false positives. This led to procedural changes
implemented by DHHS. (Under the Influence, 1994).
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Regulation of private industry drug testing labs
While it was estimated in 1992 that over 7 million Americans were subject to federal
government drug testing requirements (The medical review, 1992), in the past decade
private industry has also increased the use of drug testing.
More than 90% of the Fortune 500 companies report drug testing their employees
(DeCew, 1994). Drug testing laboratories compete for the estimated $500 million dollar
annual drug testing market (Newman, 1994).
Both the Senate and House considered legislation every year from 1988-1991 which
would require that all laboratories which analyze urine samples for drugs for U.S.A.
companies be certified and meet DHHS requirements. The most aggressive plan was
presented by a House Subcommittee in 1991. Entitled the "Drug Testing Quality Act,"
(HR33) the legislation would not only have required that all drug testing in the US be
conducted in accordance with or exceed the guidelines set forth by HHS, but also that
laboratories and lab personnel who "knowingly" violate the standards would be liable for
substantial civil and criminal penalties (US House, 1991). HR33 was never passed nor
even brought before the entire House. Drug testing for private industry remains in 1996
largely unregulated.
Too Costly
After 1991 drug testing standards for federal employees may have if anything,
loosened. In November 1992, the General Accounting Office (GAO) published a
report entitled "Employee Drug Testing: Opportunities Exist to Lower Drug Testing
Program Costs."
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Utilizing the agency reports to DHHS and the DHHS semi-annual survey, GAO found
that direct costs o f federal civilian drug testing were $7.6 million for the period from
October 1990-September 1991.
The direct costs in dollars were broken down as: 3.4 million for laboratory analyses, 3
million for sample collection, 1 million for medical review o f test results and 0.2 million
for purchase of blind performance test samples (GAO, November 1992). These exorbitant
costs existed despite only about 0.5% o f the samples tested were verified as positive.
To reduce costs GAO recommended eliminating the Medical Review Officer's (MRO)
review o f negative samples, reducing quality assurance programs, reducing frequency o f
sampling and collecting samples in house. HHS decreased the number of blind
samples required and decreased the frequency of blind challenges (from 6 to 4 per year)
when it revised the guidelines in 1994. (DHHS, June 1994).
The semi-annual survey published by DHHS which covers the period from October
1992-March 1993 listed 2.0 million dollars in direct costs for the 6-month period (DHHS,
June 1995). The most recent semi-annual survey covering October 1993- March 1994
still lists 1.6 million direct testing costs, while testing 30% fewer employees than the Oct
1992-March 1993 period. (DHHS, February 1996).
Although laboratory testing represented the largest percentage o f direct costs, GAO
did not propose to alter the immunoassay screening and GC/MS confirmation.
Rather in the updated guidelines, DHHS authorizes the use of an additional immunoassay
to "minimize possible presumptive positives due to the presence of structural analogues in
the specimen." (DHHS, 1994, section 2.4 (e)(4)).
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The guidelines continue to mandate the confirmation o f positive samples by GC/MS.
Such testing is extremely costly; expenses average $58 per person tested (DHHS,
February 1996).
The costs o f laboratory testing is indeed a critical factor for many companies. Typically
a screening tests runs $15-25, with the confirmation rising to $75 (Drug testing methods,
1990).
A GAO investigation on testing in the private sector found numerous companies
completely omitted confirmatory testing. Some private industry companies report retesting
positive samples with the same test (i.e. usually an immunoassay screen). (GAO, 1988).
McMillan (1989) citing both this report and a study conducted by Thomas-Holladay
(1989) wrote "it is most unfortunate that with the widespread proliferation o f drug testing
programs many companies do not perform any confirmatory testing."
On-Site Testing
Recently numerous companies have opted for less expensive alternatives to the
immunoassay screen/GC-MS confirmation. Confirmation by GC/MS not only involves
labor consuming and time consuming preparations and separations, but also highly trained
personnel.
Syva the manufacturer o f enzyme multiplied immunoassay (EMIT), in its 1990
pamphlet entitled "Emit Drug Abuse Assays: How Accurate Are They?," does not stress
the need to confirm the screening results by GC/MS. While GC/MS is mentioned as a
reference method, Syva recommends confirmation by a method with comparable
sensitivity (GC/MS is significantly more sensitive), but which differs chemically.
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Syva also contends that "repeating the test or obtaining verbal corroboration from the
suspected user may be adequate confirmation." (Syva, 1990)
In contrast, one o f the manufacturers o f radioimmunoassay, Roche, includes a warning
with each o f its procedures to confirm positive results by GC/MS.
On site testing is the latest tool used by some private companies. David Evans an
attorney specializing in drug testing, has written a series o f articles on the use of non
instrument, on-site testing. Evans contends that on-site testing may actually be superior in
court since there will not be a question o f loss of chain o f custody (i.e. the employee is
assured that it is actually his sample). (Evans, April, 1992). Evans further contends that
while non-instrument on-site tests are not as accurate as GC/MS, they are as accurate as
many laboratory tests, and on-site testing does not require the use of trained laboratory
technicians to perform the testing. (An Interview with David Evans, December 1992),
(Evans, January/February 1992).
Towt and his Roche Diagnostic Systems colleagues (1995) reviewed the performance
of the onsite ONTRAK TESTCUP which contained immunochromatographic reagents.
The TESTCUP system was found to be similar to other immunoassays in reactivity and
accuracy for the analyses o f benzoylecgonine, morphine and marijuana (THC).
Similarly a study by Jenkins, Darwin, Huestis, Cone, and Mitchell (1995) reinforces the
need to confirm the onsite AccuPENCH THC test (a competitive enzyme immunoassay),
with GC/MS.
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DuPont, Saylor and Shiraki (1993), reviewed a number o f immunoassay on-site drug
testing products. These products which are about the size o f a standard playing card
included immunoassays from Roche, Abuscreen & On-Trak, Hycor*s accuPINCH, EZ
Screen manufactured by Editek, Drug Screening System Triage o f Biosite Diagnostics,
and ASCEND Multiimmunoassay.
While the authors recommend on-site testing for cost effectiveness and speed of
analyses, they also note that questionable or challenged results of on-site testing should
always be retested with the currently accepted "gold standard," gas chromatography/ mass
spectroscopy at a reference laboratory. (DuPont, Saylor and Shiraki, 1993).
Statem ent of Problem
In an era when the U.S. government is combating unprecedented financial deficit is it
only a matter o f time until the extensive requirements DHHS promulgated for federal drug
testing are revised? Costs exceed more than $23,000 per positive test result. (DHHS,
6/95). Utilizing SAMHSA (Substance Abuse and Mental Health Services Administration)
surveys covering October 1992-March 1994, that federal civilian drug testing costs were
approximately 12 million dollars per year for 1993 and 1994. The testing covered
approximately 70,000 employees per year. (DHHS, 6/95, 10/95, 2/96).
Specifically the laboratory analysis is the most costly aspect of the entire testing
process and government regulations for laboratory analysis exceed those used in most of
private industry. GAO has already recommended a number o f changes which DHHS has
implemented.
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Methodology o f the screening immunoassay has improved dramatically in the past
decade. Detection limits have decreased, problems such as ibuprofen interference on the
EMIT marijuana screen have long since been resolved (Mac Donald, 1990). Some
manufacturers contend that immunoassays may be adequately confirmed by repeating the
test and even contend that some alleged "false positives" are caused by a failure in the
confirmatory testing procedures (Syva, 1990).
Gas chromatography/mass spectrometry is clearly the "gold standard" of drug testing,
its use helped to eliminate and resolve a number o f erroneous results in the 1980's.
However GC/MS is also riddled with time consuming preparations and separations,
expensive equipment and the necessity to have highly trained personnel. With the large
body o f knowledge that exists regarding the immunoassay screens and potential
interferences, is it necessary to continue the use o f GC/MS as the "gold standard" of
confirmatory testing?
Research Questions
Have immunoassays used for drug testing improved to such an extent that confirmation
by GC/MS is no longer necessary? Is there a difference between the results obtained by
the immunoassay and GC/MS for each o f the five major drugs and metabolites tested in
the federal civilian workforce?
Purpose of the study
The purpose o f this study is to determine, under the same analytical conditions (i.e.
federal agencies which follow DHHS guidelines and utilize DHHS certified labs), whether
a difference exists between the number o f positive test results from the screening test and
number o f positive confirmatory tests.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

11

Which of the five major drugs or metabolites marijuana (THC), cocaine
(benzoylecgonine), amphetamines/ methamphetamines, opiates,phencyclidine
has the lowest positive predictive value(PPV) - and thus least likely that the positive
screening test is indicative o f a true positive? Which has the highest PPV?
Assumptions
1. All collection and testing was done in accordance with DHHS guidelines.
2. The laboratory utilized a FDA approved immunoassay and GC/MS confirmation.
3. Only samples which tested positive on the immunoassay screen were submitted for
confirmatory testing.
4. All lab personnel were trained in accordance with HHS and agency requirements.
5. Contract laboratories accurately submitted to each agency a synopsis of agency samples
tested, number screened positive for each drug or metabolite, and number confirmed
positive for each drug or metabolite.
6. Blind Performance Test Specimens (BPTS's) were included in the monthly statistical
summaries.
Limitations
1. Some laboratories (e.g. Navy labs) perform two radioimmunoassay (RIA) screens prior
to confirmatory testing. Would expect therefore a higher percentage o f samples to be
confirmed, since second screen would help eliminate "random" errors o f carryover,
cross contamination.
2. Since only samples which screen positive are submitted for confirmatory testing, this
study will not generate "false negative" rates.
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3.Statistical differences between results obtained from immunoassay and confirmatory
testing will be underestimated for the above reason.
4. There are differences in interferences between immunoassays. Thus comparisons
should identify which immunoassay method was used.
5. Differences exist between threshold limits of screen (immunassay) and confirmation
Gas Chromatography/ Mass Spectrometry test. GC/MS is better able to quantitate and is
more sensitive than any o f the initial immunoassay screens.
6. The screening cutoff limit for marijuana was lowered from 100 ng/ml to SO ng/ml in
June 1994
7. Some data was obtained from contract labs via agencies as a direct response to FOIA
request, nearly two years after it was initially derived.
8. Any missing months o f agency data will necessitate insertion o f data by the
researcher, using agency monthly averages.
Definition of terms
Amphetamines- general term to describe synthetic ephedrine derivatives. Structurally the
compound contains a phenyl group with an amino group on the side chain.
Analyte- substance being measured (e.g. codeine, phencyclidine).
Blind Performance Test Specimens (BPTS's)- prepared urine samples (blind samples)
spiked with known levels o f drugs or drug metabolites, used to monitor the performance
o f the drug screening laboratory. BPTS's appear to the laboratory analyst as routine urine
samples.
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Cannabinoids- cannabis sativa is an Indian hemp plant that contains a psychoactive
component identified as delta-9-tetrahydrocannabinol ( A 9-THC). "Marijuana" is the
common term for the leaves and flowers.
Chain of custody- procedures to account for the integrity o f each urine sample by
tracking its handling and storage from the point of specimen collection to final
disposition o f the sample.
Cocaine- an alkaloid o f the plant Erthroxylon coca, a central nervous system stimulant.
Chemically the structure is benzoylmethylecgonine. The two main metabolites are
benzoylecognine (35-45%), and ecgonine methyl ester (32-49%).
Confirmatory test- a second analytical procedure to identify the presence o f a specific
drug or metabolite, which is independent o f the initial test and which uses a different
technique and chemical principles from that o f the initial test in order to ensure reliability
and accuracy. Currently gas chromatography/ mass spectrometry is the only confirmatory
approved by DHHS for the analysis o f urine samples for drugs of abuse.
Cross reactivity- In immunoassays, interaction of antibodies with substances similar to
drug that assay was designed to measure.
Cutoff limit- (or threshold limit), established by DHHS for each instrument, drug
/metabolite, level at or above which the sample will be classified as positive.
Detection limit- lowest analyte concentration that can be reliably measured. Detection
limits are always lower than cutoff limits. (I.e. detection limit o f a THC RIA 1-5 ng/ml.)
False negative- apparent absence of a drug or drug class which is in fact present in the
sample at or above the pre-established cutoff limit.
False positive- apparent presence of a drug or drug category which is not in fact present.
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False presumptive positive- positive test result on the initial immunoassay screen, which
is not confirmed to be positive by the second GC/MS confirmatory test
FOIA- Freedom of Information Act
Immunoassay- screening test based on the principle o f competition between (added)
labeled and unlabeled antigen (drug) for binding site on a specific antibody. There are
three basic immunoassays Radioimmunoassy (RIA), Enzyme Multiplied Immunoassy
(EMIT or ELA), and Fluorescence Polarization Immunoassay (FPIA).
Interference- a part o f the sample other than the target analyte under investigation which
can or did cause a response in the analysis. Interferences may contribute to either false
positive or false negative results.
M atrix effects- interferences caused by physiological sample constituents (e.g. proteins,
electrolytes), rather than the target analyte, may results in enhancement, suppression or
other alteration o f results.
Metabolite- compound produced from chemical changes of a drug in the body.
Medical Review Officer (MRO)- a licensed physician responsible for receiving
laboratory results who has knowledge o f substance abuse disorders and has appropriate
medical training to interpret and evaluate an individual's positive test result together with
his or her medical history and other relevant biomedical information.
Opiates- a class of narcotic drugs manifesting sedative, mood-altering and analgesic
properties. They include the naturally occurring alkaloids from opium- morphine and
codeine, semisynthetic opiates such as heroin, oxycodone and hydromorphon. Morphine
and codeine are derived from unripe seed capsules of the poppy plant.
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Phencyclidine- l-(l-phenylcyclohexyl)piperidine (PCP) was first used as an experimental
general anesthetic under the trade name Semyl. PCP is synthesized with relative ease and
has psychotic side effects.
Positive Predictive Value (PPV)- likelihood that a positive screening test is predictive of
actual drug use.
PPV = true positives (or GC/MS positives’)
Positives on screening test
Presumptive Positive- sample which has been flagged as positive by a screening test but
has not yet been confirmed by an equally sensitive alternative chemical method (GC/MS).
SAMHSA- Substance Abuse and Mental Health Services Administration a subdivision
of the Department o f Health and Human Services (previously National Institute of Drug
Abuse or NIDA). Responsibilities include monthly listing of all laboratories approved by
DHHS to perform federal civilian testing, and compilation o f semiannual surveys on
federal drugfree workplace programs.
Screening tests- used to detect potential drug users and eliminate from further testing
specimens that are drug free. Screening tests must have low detection limits, and be
relatively specific and sensitive. Only FDA approved immunoassays have been authorized
by DHHS for use as screening tests for federal employees urine tests.
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Sensitivity- likelihood that a test will give a positive test result when the drug is actually
present.
TP x 100 = SENSITIVITY , where TP=true positive
TP+FN
FN= false negative
Alternatively sensitivity has also been defined in drug testing literature as the ability o f a
particular screening test to differentiate among a class o f drugs- e.g. ability to discriminate
between morphine and codeine opiates.
Specificity- likelihood that a test will give a negative result when the drug is absent.
TN x 100 = SPECIFICITY, where TN= true negative
TN+FP
FP = false positive
Testing Designated Position (TDP)- Civilian positions which the federal government,
Department o f Justice and federal courts have determined have met the criteria for random
drug testing.
Verified positive test result- a test result that has been screened by a FDA approved
immunoassay, confirmed by GC/MS assay to be at or above the cutoff limits established
by HHS, and determined by the Medical Review Officer to have no legitimate medical
reason for the drugs presence in the employee's system.
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CHAPTER H
LITERATURE REVIEW
Scope o f the literature
The review o f the literature was limited to the period immediately preceding the issuance
o f EO 12564 (i.e. 1985), until the present. It focused on immunoassays, GC/MS and
federal testing programs.
Review o f the literature
There is a multitude o f literature regarding the efficacy of various immunoassays and
GC/MS for the analysis o f marijuana (THC-COOH metabolite), cocaine (benzoylecgonine
metabolite), opiates, amphetamines/methamphetamines, and phencyclidine.
Most comparisons of immunoassays include a description for a valid screening test and
provide an overall explanation of the technique. Screening tests, also called presumptive
tests, are in general initial sorting procedures to eliminate from further consideration those
samples which are drug free or contain drugs below the established cut-off level.
Conversely screening tests also highlight for further consideration (i.e. confirmatory
testing), those samples which apparently contain one or more target drugs (or metabolites)
at or above their respective threshold or cut-off level (Dubowski, 1990).
As noted by the Council on Scientific Affairs [COSA] (1987), while screening tests
strive for maximum sensitivity, some weakly positive samples will be interpreted as
negative owing to sensitivity or precision limitations (Blanke, 1987).
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It is impossible for any screening test to correctly identify 100% of the positive test
results and 100% of the negative test results. This is especially true near the detection
limit o f the instrument. (Jenny, 1989).
Inherent in the DHHS selection of FDA-approved immunoassays as the screening
choice for urine samples, and the DHHS determination o f where the cutoff limits should
be for particular drugs, is the recognition that immunoassays will results in a certain
percentage o f false negatives.
Although false negatives are best avoided since a negative test result ends the testing
process, while presumptive positives are submitted for confirmatory testing by GC/MS,
from the employee/employer standpoint, the negative consequences of a false positive test
result (i.e. loss o f job, possible criminal charges), many believe it is perhaps best to err on
the side o f false negatives.
Immunoassays
Immunoassay techniques involve competition between the sample containing the drug
to be tested and a labeled (or added) drug, for binding sites on the specific antibody to the
drug. As described by Hawks (1986), the antibodies are protein substances with sites on
their surfaces to which specific drugs or drug metabolites will bind. These antibodies are
formed by inoculating animals with appropriate immunogens (e.g. sheep antibodies are
often included in the immunoassay kits).
The differences in methodology between various immunoassays lies in the manner in
which the antibody has been produced, incorporated into the system (suspended in media,
bound to solid surface), and the actual binding to the antibody (The medical review, 1992).
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There are three major categories of FDA-approved immunoassays. Enzyme multiplied
immunoassay (EMIT or EIA), is marketed by Syva Corporation; fluorescence polarization
immunoassay (FPIA) marketed by Abbott labs under the trade name TDx and ADx,
radioimmunoassy (RIA) marketed under the name Abuscreen by Roche Diagnostics; and
as Coat-a-Count by Diagnostic Products Corporation. (The medical review, 1992).
Hawks (1986) contends that the differences between immunoassays is mainly in the
indicator that is used. Smith and Joseph (1989) explain, by the amount o f drug present
measured via radioactivity (RIA), fluorescence (FPIA), or enzyme activity (EMIT).
Radioimmunoassay
Radioimmunoassay (RIA) is the oldest immunoassay method. The sample and a known
quantity o f radiolabeled drug are combined with antibodies and allowed to equilibrate. The
excess unlabeled drug must be separated from the drug bound to the antibodies before
drug concentrations can be determined by gamma counting equipment. There is an inverse
relationship between the gamma count and drug concentration. (Montagne, Pugh, and
Fink, 1988). A positive test specimen is identified when the radioactive counts are equal to
or lower than those o f a positive control prepared in the same manner as the unknown
urine (Hawks, 1986).
Schwartz (1988) identifies the advantages o f RIA as: low limit of detection, small
sample volume required, automation o f pipetting and counting, and reasonable cost o f
testing. Disadvantages include use of radioactive substances, obligatory separation o f free
and bound fractions, high equipment costs and relatively slow turnaround times.
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[COS A] (1987) lists several other problems with RIA: needs special training in use
o f radioactive substances, and expensive gamma counter, discrete tests (only one drug
may be tested at a time), adulterants may cause false presumptive positives, linearity of
response and cross reactivity with other drugs may produce both false negatives and false
positive results. Others list the handling, storage and disposal o f radioactive wastes as a
liability ([SATC], 1988; Mandel, 1992).
Armbruster, Schwarzhoff Hubster and Liserio (1993), have used RIA successfully for
years, but note the methodology suffers from short reagent shelf life, lack of automated
analysis and waste disposal requirements.
Enzyme Multiplied Immunoassay
Concerns with the handling of radioactive material, licensing, etc. do not arise with
enzyme multiplied immunoassay (EMIT or EIA). Introduced in 1972 by Syva, urine is
mixed with a specific antibody and enzyme substrate. The enzyme activity of the drug is
measured. (Smith & Joseph, 1989).
EMIT is based on the immunochemical recognition of the three dimensional molecular
structure o f the drug (Schwartz, 1988). There is an inverse relationship between the extent
o f enzyme indicator reaction and the drug concentration in the sample (Montagne et al,
1988). Most clinical labs currently use EMIT, it has the advantage o f a nonisotopic
endpoint that can be measured photometrically. In contrast with RIA, analysis time is
short and it is a homogeneous assay requiring no separation step for free and bound
fractions ([SATC], 1988).
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Mandel (1992) contends that EMIT is less sensitive than FPIA or RIA and less precise
at low drug concentrations. EMIT is prone to cross reactivity (Cone, Dickerson, Paul and
Mitchell, 1993). False or unconfirmed positives may result from temperature changes in
the sample (DeCew, 1994); (Smith and Joseph, 1989).
Armbruster et al discussed the potential for carryover using EMIT technology
following the analysis o f samples with high drug content, particularly cocaine. Schwartz
(1988), contends that the ease of adulteration is another disadvantage.
Fluorescence polarization immunoassay
Fluorescence polarization immunoassay (FPIA) is a competition between drugs in the
urine and fluorescent drug analogue for limited sites on the antibody. (Schwartz, 1988).
If large amounts o f drugs are present, less fluorescent drugs will bind to the
antibody. The reaction mixture is exposed to plane polarized light of a wavelength that
will excite the fluorescent label.
Among the advantages o f FPIA is the lack o f radioactivity, its ease of operation, speed
and ability to yield quantitative results automatically. It is highly sensitive but susceptible
to sample adulteration ([COSA], 1987).
At least two other studies confirm the proclivity for FPIA results to be adulterated.
SchwarzhofF and Cody (1993), studied various potential adulterants and concluded that a
number are capable o f causing false negative results. Baiker, Serrano and Lindner (1994)
also found that adding bleach created some false negatives for FPIA results.
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Kinetic Interaction of Microparticles in Solution (KIMS)
In 1992, a new immunoassay methodology was introduced by Roche called kinetic
interaction of microparticles in solution to be used with Roche ONLINE assays.
(Armbruster et al,1993). KIMS is an extension o f Roche's ONTRAK assays which utilize
latex immunoassay techniques.
As described by Armbruster et al (1993), with typical immunoassay technology the
drug of interest is conjugated to a "tag" or analytical signal, such as a radioisotope,
enzyme or fluorescent molecule. With KIMS, the analytical signal is produced by
microparticles. Just as with the other immunoassay technology, when a urine
sample containing the drug o f interest is mixed with reagents, unconjugated drug in the
sample will "compete" for antibody binding sites, the amount o f lattice formation "is
inhibited proportional to the concentration of the drug in urine." (Armbruster et al, 1993).
The absorbance difference between the first and final readings decrease with higher drug
concentrations.
Recently both ONTRAK (latex) and ONLINE (KIMS) have been increasingly utilized
by DHHS accredited laboratories. In feet the Laboratory Corporation o f America which
performs testing for the Department o f Transportation, reports that it utilizes KIMS on
approximately 90% o f the screening samples. (Personal communication, May, 1996).
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Gas chromatography/ mass spectrometry confirmation
Gas chromatography/mass spectrometry (GC/MS) combines the chemical separating
power o f the gas chromatograph "fingerprinting", with the molecular identifying power o f
the mass spectrometer ([COS A], 1987). Drugs are identified with GC/MS by their gas
chromatographic retention time and by ions that form in the mass spectrometer (Schwartz,
1988).
GC/MS can be operated in several modes. As pointed out by the Clinical Chemistry
substance abuse testing committee (1988), with high drug concentration the mass
spectrometer can be operated in the "full scan" mode.
In this mode the complete mass spectrum of the analyte is presented, from its
molecular ion to the fragments formed by the ionization process. This "fingerprint"
provides the most conclusive identification of the compound. This identification can be
based on matching o f the mass spectrum with those contained in the MS library.
Alternatively the mass spectrometer can be operated in the selected ion monitoring
mode. In this mode only the currents o f a few fragments characteristic o f the analyte are
monitored.
Preparation of samples for GC/MS is often labor and time consuming. Extraction
techniques are utilized in which the drug or analyte is separated by a procedure designed
specifically for that analyte. Most GC/MS procedures chemically change the analyte to
form a derivative (The medical review, 1992).
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Urine testing of drugs of abuse
Opiates
Morphine, codeine and semisynthetic derivatives o f morphine (i.e. heroin) belong to
the class o f drugs called opiates. Heroin (diacetylmorphine) is strictly a drug o f abuse,
whereas morphine and codeine are commonly used in analgesics and cough medicines
and are often prescribed. (Hawks and Chiang, 1986).
The Department of Health and Human Services guidelines require the analysis of
codeine and/or morphine above the cutoff limits and clinical evidence by the Medical
Review Officer to verify illegal use o f opiates. Heroin may only be verified with clinical
evidence (heroin tracks) or by a confirmation o f the presence of 6-monoacetylmorphine
with GC/MS. (DHHS, 1994).
Part o f the exceptional provisions that DHHS put in place to verify opiates are due to
the extended use o f opiates in nonprescription drugs, prescription drugs, their
crossreactivity, and availability in everyday foods (like poppy seeds).
There have been a series o f studies conducted on poppy seed cakes, muffins, rolls, etc.,
which point to positive morphine results caused by the poppy (opiate) seeds. Positive
results may occur approximately 3 hours after ingestion o f one to two rolls or muffins.
([SATC], 1988). McCutcheon and Wood (1995), recently conducted a study on Nabisco
Sociables crackers, and affirmed a positive test result (both screening and confirmatory
testing) approximately 2 hours after ingestion o f a half-box.
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Metabolically codeine and morphine often coexist in urine samples. Cone et al in 1993
noted that heroin is rapidly metabolized by hydrolysis to morphine; morphine and codeine
are metabolized by oxidation and coupling mechanisms.
Heroin use may be distinguished from morphine or codeine intake by the detection of
6-monoacetylmorphine, a specific marker for heroin use (Tai, Christensen, Paule, Sanders
and Welch, 1994).
Lin, Lafolie, and Beck (1994) conducted a study assessing the measurement o f urinary
opiates, and noted that due to heroin's rapid metabolisis, it is not reliably detected. The
analytical target, 6-acetylmorphine may be detected only for a relatively short time (less
than 8 hours), after intake. Lin and the others note that the hydrolysis step in the
confirmation process o f opiates is critical. A failure to do so properly may result in
erroneous conclusions.
Another study conducted by Fuller and Anderson (1992) reached a similar conclusion.
They found that the failure to analyze samples promptly and/or refrigerate them led to the
loss o f significant amounts o f 6-acetylmorphine by hydrolysis.
Smith and his colleagues (1995) reviewed the effect o f various prescription opiates
often given as analgesics or antitussives on various opiate immunoassays. Oxycodone
(Percodan©) is one o f the most commonly prescribed drugs in the opiate series (classified
as 6-keto-opiods). The researchers concluded that nearly all o f the semisynthetic drugs,
specifically hydrocodone, hydromorphone and oxycodone could crossreact and cause false
presumptive positive test results for TDx, Abuscreen or EMIT.
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Cone et al (1993) conducted another comprehensive study o f the four commercial
opiate screening immunoassays. They administered known amounts o f codeine, morphine
and heroin to healthy male volunteers. Cone and his colleagues concluded that less than
5% of heroin and morphine specimens tested as false negatives by each o f the
immunoassays.
Some codeine specimens were identified as false positives by TDx, Abuscreen and
EMIT as a result o f multiple codeine metabolites.(Cone et al, 1993). EMIT demonstrates
significant cross reactivity. The CAC test was specific for free morphine and thus gave
numerous false presumptive positives for codeine.
A unique 1990 Rockwell International blind study which included known interferences
o f the EMIT screening tests, found that opiates have the highest false positive rate o f any
o f the drugs o f abuse. The study reports more than 5% false presumptive positives for
opiates. (Knight et al, 1990).
Ferrara and his colleagues (1994) conducted an intensive study comparing nine
different screening techniques for various drugs o f abuse. The Italian forensic toxicologists
reported high false positive and false negative rates (7.9% and 8.0%, respectively) for
opiates by Coat-a Count RIA. The FPIA ADx assay was slightly better (6.3% false
presumptive positives and 6.5% false negatives).
EMIT I showed the lowest false positive rate (2.8%) but still had a high false negative
(6.9%). All test results (positive and negative) were confirmed with another analytical
technique and GC/MS. (Ferrara et al., 1994).
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Cannabinoids/ Marijuana
Delta-9-tetra hydrocannabinol (THC) is the primary psychoactive ingredient present in
the leaves and flowering tops o f cannabis plants. THC is rapidly transformed by the liver
enzymes to several metabolites- the primary one is 1l-nor-delta-9-tetra hydrocannobinol9-carboxylic acid (9-carboxy-THC). (Hawks and Chiang, 1986).
THC is approved by the Food and Drug Administration and marketed under the trade
name Marinol®, for two purposes as an antiemetic for cancer patients utilizing
chemotherapy and as an appetite stimulant for AIDs patients. (ElSohly and Jones, 1995).
Cannabinoids are hydrophilic molecules subject to adsorption to solid surfaces from
aqueous solutions, such as urine. (Blanc et al, 1993).
Haver, Romson and Sadrazadeh (1991) also point out the tendency for THC to adhere
to a variety o f surfaces. In their study, Haver and the others found numerous instances of
false positive EMIT results due to carryover from previous high drug samples. The study
lists carryover as a known problem with high volume analyzers especially if there is
inadequate washing o f the probe between analyses.
In the late 1980's Ibuprofen (Advil™, Motrin™) was reported to cross react and
produce presumptive false positives with several immunoassys for THC. (U.S. House,
1987). The manufacturer however, took steps to rectify the problem; ibuprofen is no
longer an interferent in the analysis o f cannabinoids. (McBay, 1989). Despite anecdotal
stories to the contrary, melanin metabolite from dark skinned persons also does not
interfere with the EMIT screen (Schwartz, 1988).
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Perhaps more than any other drug-of-abuse, cannabinoid immunoassys are prone to
successful adulteration and subsequent false negative results (SchwarzhofF and Cody,
1993). Baiker et al (1994) reported the addition of bleach causes decreased THC
concentrations and potential false negatives for each immunoassay.
Altunkaya and Smith (1990) cite several instances o f aberrant RIA cannabinoid results
(both false positive and false negative). The researchers believe the erroneous results were
caused by proteinaceous interfering materials; high blood proteins in urine produced
erroneously low radioimmunoassay results.
There have been a series o f studies dealing with the stability o f THC, and THC
derivatives. Paul, McKinley, Walsh, Jamir and Past (1993) found due to its lipophilic
nature and low solubility, freezing samples led to a decrease in THC concentration.
However, another study by Dugan, Bogema, Schwartz and Lappas (1994) disputed this.
It is clear whether due to lipophilic action, adherence to walls, cross reactivity of
immunoassays with other cannabinoid metabolites, or some other reason, that GC/MS
results which are specific for the THC-COOH metabolite are often lower than expected
from the initial immunoassay screen.
Blanc et al (1993) found that A 9-THC concentrations in calibrators and controls have
been observed to decline in normal use. This makes quantitation more difficult.
Nonetheless most toxicologists report that cannabinoid immunoassays have
consistently given reliable assessments o f illegal drug use with few false presumptive
positives and with the lowering o f the cutoff for cannabinoids from lOOng/ml to 50 ng/ml
has resulted in few false negatives (Huestis, Mitchell and Cone, 1994).
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The study conducted by Ferrara and his colleagues (1994) found higher false positive
(FP) and false negative (FN) rates than previously reported. Ferrara reported for ADx
(FPIA) a false presumptive rate o f 6.0%, 2.7% false negative. RIA (CAC)- 4.7% FP,
2.4% FN, and EMIT-1 2.5%FP, 10.4%FN.
Armbruster and his associates (1993), compared immunoassay techniques for the
analysis o f several drugs including marijuana. They found RIA and ONLINE (KIMS)
detected 99% o f the confirmed positive samples. TDx detected 95% o f confirmed
positives and EMIT 88%. The researchers concluded the performance o f EMIT was
comparable to previous studies.
Cocaine
Cocaine (benzoylmethylecgonine C 17H 21N O 4) is mostly excreted in metabolized
form. The two major metabolites in urine are benzoylecgonine and ecgonine methyl ester.
It has been estimated that total dose eliminated is approximately 46% benzoylecgonine
(BE) and 41% ecgonine methyl ester (EME) ([SATC], 1988).
A number o f studies document the major metabolites o f cocaine and their usefulness
as an indicator o f illegal drug use. (Hippensteil and Gerson, 1994). The benzoylecgonine
metabolite can be detected for a longer period than either the nonmetabolized cocaine or
ecgonine methyl ester (48-72 hours by EMIT, 96-144 hrs. by RIA).
Hombeck, Barton and Czamy (1995) note that cocaine has the shortest detection time
in urine o f any o f the five major drugs monitored by DHHS.
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Several studies evaluate the effectiveness o f different immunoassays in the analysis o f
urine samples for cocaine metabolite(s). Armbruster and his colleagues (1993) have
experienced an occasional carryover problem following the analysis of a high cocaine
sample in their Air Force laboratory. They found a carryover problem occured with RIA,
KIMS and EMIT. Yet Armbruster et al document excellent results for screening o f
cocaine as well as an excellent correlation between screening and confirmatory results.
RIA detected 99.6% of confirmed positive samples, EMIT-99.3%, and TDx-98.9%.
Another study by Hailer, Glienke, Schwab and von Meyer (1995), compared the
analyses o f EMIT d.a.u. and modified ONLINE KIMS method. The researchers found
both systems effectively identified positive cocaine samples.
While the results obtained by Armbruster were not completely corroborated by Italian
toxicologists Ferrara et al's 1994 study, the second study did find that cocaine
immunoassays gave the best overall results/correlation of any of the drugs o f abuse.
Ferrara and the others found EMIT-1 gave a false presumptive positive rate o f 0.9%, a
5.6% false negative (FN) rate. FPIA results were: 0.5% FP and 8.8% FN. RIA: 0.7% FP,
1.7% FN.
Phencyclidine
Phencyclidine (PCP) is one of a series o f arylcyclohexylamines that produce similar
psychotic effects. PCP undergoes oxidation and conjugation in the body. Unchanged PCP
is excreted in the urine in moderate amounts (10% of the dose). (Hawks and Chiang,
1986).
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The nonmetabolized PCP which is excreted in the urine is actually what is measured in
the laboratory. Immunochemical methods are relatively specific for PCP.
Immunoassay false positives have been reported with the administration o f thoridazine
(Mellaril™), dextromethorphan (found in prescription cough medicines) and
chlorpromazine (Thorazine™) (Smith and Joseph, 1989). Other RIA interferences include
diazepam (found in valium) and imipramene (tricyclic antidepressant) (U.S. House, 1987).
Additional potential cross reactive prescription and nonprescription medications
reported for RIA and EMIT include: diphendramine, doxylamine, and meperidine
([COSA], 1987).
When threshold limits were first established for phencyclidine by HHS in 1988 at 25
ng/ml for the screening immunoassay, only RIA had a significantly low detection limit to
accurately assess urine samples for PCP. Since that time the Syva corporation has
developed a new immunoassay (EMIT 700) with acceptable accuracy and detection
limits, the previous EMIT assay had a detection limit of 75 ng/ml. Syva also developed a
procedure to adapt its previous unit with a 25 ng/ml calibrator. Cary, Johnson, Folsom
and Bales's 1992 study reported that the Emit d.a.u could be successfully adapted.
In 1993 Schwarzhoff and Cody found PCP assays remarkably insensitive to
adulterations.
Neither Armbruster (1993) nor Ferrara (1994) whose comprehensive immunoassay
comparisons discussed most o f the drugs o f abuse covered phencyclidine. According to
Armbruster "too few positive samples were found to allow a method comparison."
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Ferrara's study excluded phencyclidine since Italian epidemiological data did not show
it to be among the major abused drugs.
One o f the few comparisons of immunoassays for the detection o f PCP in urine was
conducted by Caplan and Levine. (1989). Caplan and Levine compared the TDx, ADx
and EMIT d.a.u. assays for phencyclidine. All immunoassays tested correctly identified
50 urine samples which contained phencyclidine.
Amphetamines/ Methamphetamines
The term amphetamines encompasses not only amphetamines and methamphetamines
(N-methyl derivatives of amphetamine), but also several other chemically related
phenethylamines that are easily available in "over-the-counter" preparations. These
substances usually are phenylpropanol amine, pseudoephedrine, and phenylephrine-each
o f which has the potential to interfere with the screening immunoassay. ([SATC], 1988).
There exists a special need to confirm amphetamines so that the specific substance is
accurately identified. While the developers of the DHHS guidelines were aware of the
difficulty evaluating amphetamines and methamphetamines due to numerous interferences
with the screening immunoassays, they were perhaps unaware of the problem with
confirmatory testing until the late 1980's and early 1990's.
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As previously discussed in the introduction o f this thesis, there were a series o f notices
in the federal register regarding the suspension and subsequent reinstatement of NIDA
certified laboratories which had misidentified methamphetamines. (ElSohly, 1992). The
problem arose when most GC/MS confirmation tests were not able to differentiate
between d-methamphetamine and legal over-the-counter 1-methamphetamine. (The d and 1
designations refer to the dextro-rotary and levo-rotary optical isomers which are mirror
images o f each other).
The inability o f many GC/MS procedures to distinguish between the two isomers is
compounded when taken in combination with the use o f legal Vicks inhalers which also
contain 1-methamphetamine. Many labs were unable to perform a chiral GC/MS assay to
separate the two isomers (d and 1isomers). (Hombeck and Czamy, 1993).
The action o f certified labs (Roche Biomedical) to misidentify methamphetamines
resulted in the firing o f some employees for illegal drug use, and subsequent expensive
litigation. (Murphy, Barlow, and Hatch, 1994).
Poklis and Moore (1995) examined the response o f EMIT immunoassays following
use of Vicks inhalers by several volunteers. They concluded that EMIT did produce false
positives following use o f Vicks inhalers in specified situations.
An extensive two-year study conducted by Hornbeck and Czamy at the San Diego
Navy drug screening laboratory, concludes that over-the-counter, prescription medications
and inhalers can cause false positive results for the illegal d-methamphetamine. They
recommend a chiral separation.
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ElSohly and his associates (1992) recommend treating samples with sodium periodate
to eliminate over-the-counter interferences.
D' Nicoula, Jones, Levine and Smith (1992) also reference the false positives at several
certified testing labs. They assert that amphetamine-like compounds
phenylpropanolamine, pseudoephedrine, and ephedrine which appear in over-the-counter
cold, stimulant and diet medications, when present in very high concentrations absent
amphetamines may produce false positives for methamphetamines.
One hypothesis for false confirmatory tests is that thermal dehydration o f ephedrine or
pseudoephedrine in the injection port or other heated zone on the GC/MS caused products
o f methamphetamine. (The medical review, 1992).
DHHS took steps to alleviate the problem by requiring quantification o f a certain level
o f amphetamines (£ 200 ng/ml) in addition to greater than S00 ng/ml methamphetamines,
in order to confirm the presence of methamphetamines. (DHHS, 1994).
Methamphetamine is slowly metabolized to amphetamine, therefore urine containing
the illegal form of methamphetamine should also contain some amphetamines.
A study by Valentine (1995) and his colleagues utilizing ten volunteers administered
d-methamphetamine, concludes that the new DHHS requirements result in numerous
false negatives.
Beyond the concerns with the confirmatory testing, the immunoassay screening o f
amphetamines and methamphetamines is riddled with complications. Armbruster et al
(1993) wrote that "amphetamine screening is traditionally a problematic activity and our
data underscores the variability that can be expected for immunoassays."
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Armbruster and the others conducted a very large study (> 50,000 samples), comparing
immunoassays. They found that agreement for the four immunoassays is not as good for
amphetamines and methamphetamines as it is for the other four major drugs o f abuse,
further Armbruster and his colleagues found a number o f unconfirmed presumptive
positives being reported by several o f the immunoassays.
Cody and Schwarzhoff (1993) further assert that "the analysis of samples for the
presence o f amphetamines and amphetamine analogues is a difficult process and no single
immunoassy holds a clear advantage over the other commercially available reagents."
Several over-the-counter preparations used as decongestants and diet aids containing
ephedrine and phenylpropanolamine (amphetamine-like compounds) are capable o f
producing false EMIT and RIA tests if present in significant concentrations.
Hawks and Chiang (1986), list several prescription drugs- benzophetamine,
fenfluramine, mephentermine, phenmetrazine and phentermine which can also produce
false positive immunoassay results.
There have been several studies comparing the efficacy of each immunoassay test for
the presence of amphetamines and methamphetamines. According to a study conducted by
DTSficoula and his colleagues, EMIT showed the greatest tendency to produce false
presumptive positives.
Roche's RIA was reported to produce false presumptive positives with
1-ephedrine, norephedrine, d-pseudoephedrine, 1-pseudoephedrine, d, 1-norephedrine, etc.
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Each o f the immunoassays exhibits strong reactivity to the d versus 1drugs for which
they are designed. Other reported false presumptive positives were caused by
chlorpromazine and fluspirilene for EMIT. (Crane, Dawson and Tickner, 1993). Rantidine
used in the treatment of gastric and peptic ulcers also caused presumptive false positives.
It is perhaps to be expected with the large body o f interferences, inability to distinguish
between legal and illegal optical isomers, that the screening o f amphetamines are the least
accurate o f any o f the major drugs of abuse.
Knight and her colleagues (1990) in their blind study of certified labs found not false
positives for amphetamines and methamphetamines, but rather the largest percentage of
false negatives (37%). Ferrara et al (1994) also found a surprisingly low false positive rate
for the immunoassays but high false negative rates, (i.e. 38% for EMIT, 44.9% for RIA).
Baker et al (1995) conducted a study comparing EMIT and ONLINE (KIMS) for the
analysis o f amphetamines. They found both immunoassays produced false positives. O f
110 positive amphetamine samples, 201 tested positive by EMIT, 137 by ONLINE. This
correlates to a positive predictive value (or agreement between the immunoassay and
GC/MS), o f 55% for EMIT and 80% for ONLINE.
Previous Studies of Drug Testing Programs
Previous studies including the most recent SAMHSA semiannual survey which covered
October 1993-March 1994, report verified positive test results for all federal civilian
employees o f approximately 0.6% of those tested (DHHS, February 1996). The report
lists cocaine tested as the most commonly abused drug of the civilian workforce (51%),
followed by marijuana at 42%.
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A thesis written by Doster and Ross (1993), describes the Air Force military drug
testing program in 1992. The Air Force reports 0.35% o f their military samples were
laboratory confirmed positive during that year. Following review by the Medical Review
Officer, 0.10% o f Air Force military personnel samples were verified positive for illegal
drug use. The 1992 positive results for the Air Force military may be broken down as:
0.32% opiates, 0.17% marijuana, 0.13% cocaine, 0.06% amphetamines, and < 0.01%
PCP.
Smith Kline Beecham clinical laboratories have provided one of the few analyses of
laboratory positive test results, in contrast to those verified test results which are reported
after review by the MRO. They reported that positive confirmatory laboratory tests had
declined from 18.1% in 1987 to 8.8% of the more than 2 million samples which they
tested in 1991. Smith Kline reported that 34.6% of the 1991 positive test results were for
marijuana followed by 29% for cocaine. (The medical review, 1992)
A more recent report from Smith Kline Beecham (1996) asserts that true positive test
results have now declined for the eighth straight year and lists laboratory positive rates of
8.4%, 7.5%, and 6.7% for 1993, 1994, and 1995 respectively.
Additionally the prevalence rates were lowest for safety sensitive transportation
workforce as compared to the general workforce (3.4% vs 7.5%) for 1995. (Smith Kline
Beecham, 1996).
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Summary of the Literature
It appears from the array of previous studies which assessed the ability o f screening
tests to accurately identify positive urine samples, that EMIT is the most widely studied.
There have been differences found between the three immunoassays, however generally all
are most accurate for the detection o f the metabolites o f cocaine and marijuana and PCP.
More difficulty exists in the analysis o f amphetamines, methamphetamines and opiates.
The most recent semi-annual survey o f federal drugfree workplace programs (DHHS,
2/96) reports that 54 agencies conducted drug testing from October 1, 1993-March 31,
1994. These agencies average slightly above 0.6% verified positive test results. (Verified
test results include a determination by the MRO whether there is a legitimate reason for a
drugs presence, andI or review o f data/ chain o f custody documents for scientific
sufficiency). However the report did not provide information or rates on the samples that
were confirmed positive for each of the five drugs/ metabolites, nor did it address
screening results whatsoever. (DHHS, Feb. 1996)
Other studies such as those reported by Smith Kline Beecham (The medical review,
1992; Smith Kline Beecham, 1996), and Doster and Ross (1993) while providing data on
confirmed positive rates, do not address differences between the results from screening
or confirmation nor deal with federal civilans or employees tested under the same stringent
DHHS guidelines.
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In the ten years that have elapsed since the issuance of President Reagan's Federal
drug free workplace program immunoassay technology has improved dramatically. There
have been many studies comparing the efficacy o f the immunoassy for each o f the five
major drugs of abuse, but most studies have been conducted in a controlled laboratory
environment. Previous studies such as those o f Ferrara, Knight, and the others while
establishing an impressive array o f data concerning the effects of adulteration,
interferences, temperature variations etc. dealt almost exclusively with BPTS's, controlled
samples and standards which they had prepared or purchased.
Conversely several studies involved administering quantities of drugs to volunteers
and monitoring drug levels over a period of time. Armbruster's study may be an exception
in that he utilized Air Force military data from his own laboratory, but again military
personnel were not subject to the same stringent DHHS requirements as their civilian
federal employee counterparts.
This study deals with how the drug free workplace and drug testing actually works in
the real world, it involves a large period o f time covering many civilian employees tested
under a variety o f circumstances The existing literature does not address these issues.
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Chapter HI
METHODS
This chapter is a summary o f the methods to be used in conducting this study. The
following topics will be reviewed: research questions, hypothesis testing, positive
predictive values, false positive rates, population, sampling selection, data acquisition and
analysis.
Research Questions
The purpose of this study was to analyze the accuracy o f immunoassays for the
detection o f positive urine samples. This was determined by comparing positive
immunoassays with the results of the GC/MS confirmatory testing. Secondly the need for
continued confirmatory testing was assessed based on those comparisons.
The following research quesions were constructed from the statement of purpose:
1. Is there a difference in the number of positive immunoassay screens and the number o f
samples which are ultimately confirmed by GC/MS? From this an even more basic
question may be derived- has immunoassay technology improved to such an extent that
GC/MS confirmation is no longer necessary, and false presumptive positives no longer
occur?
2. For which drugs/metabolites is the difference between the positive rates from the
immunoassay and positive GC/MS results most significant? Simply put, which has the
lowest positive predictive value?
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Hypothesis testing
The use o f hypothesis testing in the present study is ill advised. This thesis deals with
drug testing as it is actually performed at federal agencies. DHHS protocol requires that
all samples be submitted for screening immunoassays but only those which test positive
are subsequently submitted for confirmatory testing. (DHHS, 1994). The study is derived
not from two independent samples, but rather one very large sample.
Generally hypothesis testing with a z-test would be the statistical treatment of choice
given the size o f the sample (> 100), although it typically involves two independent
samples (Glaser, 1995).
McNemars test for correlated proportions is useful when the same subjects are
measured or observed twice. (Dawson-Saunders and Trapp, 1990). It is often utilized
when comparing subjects who have received two different medical treatments.
Determinations are made o f both false positives and false negatives by each technique. In
this study false negatives were unable to be derived since the majority o f the samples (all
which tested negative on the initial inmmunoassay), were not submitted for confirmatory
testing.
Dunn (1977) described the usage o f hypothesis testing, and z scores coupled with
McNemars test when comparing a single sample vaccination study of rubella and measles.
Nonetheless, the lack of available information on how the negative immunoassays would
have tested by GC/MS, and the dependency o f the two tests upon each other is why the ztest, McNemars test and hypothesis testing is inappropriate here.
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Positive Predictive Values and False Presumptive Positive Rates
Dawson-Saunders and Trapp (1990) note that studies which compare two methods,
where one is considered a "gold standard," often measure the accuracy o f the diagnostic
procedure by calculating sensitivity (or positive predictive value) and specificity.
Specificity or ability to detect negative samples correctly has been determined in previous
studies to be well above 99% for the immunoassays tested. (Hansen, Caudill and Boone,
1985; Dawson-Saunders and Trapp ,1990).
In this study, the accuracy o f the screening test is determined through the tests ability to
correctly identify positive samples or positive predictive value (PPV). This measures
the sensitivity o f the test. Secondly while unable to directly measure specificity since
negative sample are not submitted for confirmatory testing, false presumptive positive
rates will help to assess the "specificity" of the test (false positive rates are inversely
related to specificity).
In lieu o f hypothesis testing many scientific journals recommend the use of confidence
intervals while expressing data. This includes Lancet and the American Journal of
Epidemiology among others. Confidence levels help assess the precision o f the effect
estimate.
Dawson-Saunders and Trapp explain the current emphasis on confidence intervals on
three factors. Initially readers are reminded that estimates in the study have variability and
the same results may possibly not be replicated in another study. Secondly confidence
intervals provide the same information that a statistical test provides and more; the 95%
interval provides a summary of several statistical tests. Finally, confidence intervals are
appropriate in some studies (like this one) when hypothesis testing is not.
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Confidence intervals (95%) for a proportion in single groups are calculated in
the following manner: observed proportion(p) +/- 1.96 x Standard error o f proportion
= p +/-1.96 x (p (l-p)/n) to the 1/2 power.
Confidence intervals were computed throughout this study for positive predictive values
and for false presumptive positive rates using 95% confidence intervals. This means
that in only 5% or less cases the "true" parameter is not within the interval listed.
For instance if a false positive rate of 0.50% is derived from a sample (n) o f 1000, the
confidence interval is 0.5%+/-1.96 x ((0.5)(0.5)/1000) to the 1/2 power or 0.47-0.53%.
Population
The population of a study is defined by Babbie (1995) as that group about whom we
want to be able to draw conclusions, very rarely however are we able to study all the
members o f the population.
For this study the population o f interest is federal civilian employees.
Sampling Selection
The federal drug free workplace semi-annual survey compiled by the Substance Abuse
and Mental Health Services Administation (DHHS, 1995), for the period o f October 1,
1992- through March 31, 1993 (corresponding to the beginning of this study), lists the
six federal agencies which tested the largest number o f federal civilians. These are,
respectively: Department o f Transportation, Department of Navy, Department o f Army,
Department o f Justice, Department o f Air Force and Department of Veterans Affairs.
The six federal agencies listed above were utilized for this study since they performed
the greatest amount of drug testing. Secondly these agencies test for all five o f the major
drugs o f abuse (some agencies only test for marijuana and cocaine).
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More than one agency was chosen to generate a larger sample, to make comparisons
between immunoassays (impossible if only one agency were utilized), and to avoid reliance
upon a single agency.
Laboratories which provide drug testing services for federal agencies are required
under the Department o f Health and Human mandatory guidelines for federal workplace
drug testing programs (section 2.4 (g)(6)) to provide monthly statistical summaries to the
agency o f the number o f specimens received, reported, screened positive and confirmed
positive for each of the five major drugs/ metabolites. (DHHS, 1994).
Each o f the six agencies identified above tested under the same DHHS requirements,
during the same period and utilized FDA approved immunoassays and GC/MS
confirmatory testing.
Data Acquisition
1. A FOIA (Freedom o f Information A c t) request was made to each o f the six federal
agencies identified above, requesting monthly statistical summaries for January 1993December 1994.
2. In the event a response was not received within a two month period, a second certified
FOIA request was sent.
3. Additional requests were initiated if information received was incomplete (i.e. missing
months) or only confirmatory results submitted.
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4. If information was still incomplete after step 3, this was noted. Missing data was
asterixed, explained, and results inserted based on the monthly average o f that agency for
that year. If only confirmatory results were received, the agency was eliminated from the
study.
5. Data submitted on an annual summary basis, rather than a monthly summary was
accepted and compiled in a yearly format. All data was compiled in a yearly format.
6. Agency drug testing totals were computed for 1993 and 1994. Calculations o f false
presumptive positives, confirmed positive rates and positive predictive value for each
drug/metabolite were computed. Confidence intervals were also determined at the 95%
confidence level.
7. Contract laboratories identified as providing drug testing services for federal agencies
above were contacted in writing. The lab was asked to indicate which immunoassay
screening method used and if multiple screens were performed.
8. Laboratories which did not respond to #7, were contacted by phone, and sent a second
certified letter.
9. If more than one immunoassay method was used by the six federal agencies (i.e. some
agencies use EMIT and others RIA), comparisons were made between immunoassays.
Data Analysis
Calculations were made regarding the false presumptive positive rates for each drug of
abuse. Comparisons were also made for each immunoassay. Calculations were made o f
false positive rates and confirmed rates for each drug/metabolite and for each agency.
Calculations o f PPV and false positive rates included confidence intervals set at 95%.
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Glaser contends that to assess the quality of a diagnostic test it is critical to know
its validity and reliabilty; so also may the quality o f a study be gauged on the reliability and
validity o f both methodology and results. In this study,, the validity (or accuracy) of the
screening test is determined by a comparison with the accepted "gold standard" gas
chromatography/ mass spectrometry.
The validity o f the results are further supported by the stringent DHHS requirements to
which the laboratory is required to adhere, agency use of blind proficiency test samples,
and laboratory accreditation procedures.
Reliabilty is defined as the reproducibility, repeatibility, precision. It is inappropriate to
assess reliability with consistent confirmed positive rates, positive predictive values etc.,
because the results are dependent upon a multitude of different civilian samples.
Rather, reliabilty is strengthened by agency use of the same DHHS guidelines, covering
the same period o f time (1993 and 1994). The reliability of a study using a survey or
questionnaire is often evaluated using a pretest or test-retest (Babbie, 1995: Doster and
Ross, 1993). Clearly this evaluation method is inapplicable in this study.
Glaser (1995) believes that neither reliabilty nor validity is in question in routine lab
testing. Laboratory use o f quality control samples is indeed crucial however in the
determination o f reliability. Health and Human Services guidelines mandate the use
o f quality control samples, and blind proficiency samples.
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Chapter IV
ANALYSIS OF RESULTS
This study deals with six federal agencies which conducted the largest amount of drug
testing on their civilian employees during 1993 and 1994. Freedom of Information Act
(FOIA) requests were submitted to the Departments o f the Air Force, Army, Justice,
Navy, Transportation and Veterans Affairs, seeking copies o f 1993 and 1994 drug testing
statistical summaries referenced in DHHS mandatory guidelines for federal workplace
drugtesting programs (section 2.4 g(6), (DHHS, 1994)). Specifically this section required
DHHS certified laboratories to supply the federal agencies for which it performs drug
testing services, monthly statistical summaries of the number o f agency samples analyzed,
the number which screen positive and are confirmed positive for each drug or metabolite.
This information was in fact obtained from the FOIA offices of each agency identified
above. All data was complete with the exception of the Department of the Navy. Navy
was missing data from January, February 1993 and June 1994. Data was inserted for the
missing months, based on the Navy's monthly average for 1993 and 1994 respectively.
While each o f the six federal agencies utilized in this study conducted testing of its
civilian employees for each o f the five major drugs of abuse (or metabolites), some of the
agencies required testing o f all urine samples for the five drugs while others authorized
the testing for some testing categories o f marijuana (THC) and cocaine (benzoylecgonine),
only.
As a result, the sample size used in this study range from 65,601 urine samples for
phencyclidine, to 94,336 urine samples for benzoylecgonine.
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The most recent SAMHSA semi-annual survey discussed earlier, lists 28,199 civilian
drug tests performed in the 6 months from October 1, 1993- March 31, 1994. (DHHS,
February 1996). It is estimated that this study covers more than one-half o f the civilian
federal employees tested during 1993 and 1994.
These agencies either performed drug testing through its own DHHS certified
laboratory ( Navy), or contracted drug testing services from another DHHS certified
laboratory. The laboratories which conducted drug testing for the six agencies were
contacted during this study and asked which immunassay(s) it utilized, and if it
performed multiple screens. Only the Navy which performs drug testing services for itself
and Veterans Affairs routinely uses more than one screen on individual specimens. The
Laboratory Corporation o f America which performs drug testing services for DOT
performs an additional TDx screen, following a positive KIMS ONLINE screen and prior
to confirmatory GC/MS testing for presumptive positive amphetamines.
The Navy performs two RIA screens using both Roche ABU SCREEN and Coat -aCount, if the sample is still positive after the completion o f both immunoassays then a
GC/MS confirmatory test is performed. The Navy Drug Screening Lab at Great Lakes,
Illinois wrote "all military labs are required to perform two screening assays"(Personal
communication, 4/96).
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Table 1 lists the six federal agencies, their contract laboratories and immunoassy
utilized in the analysis o f agency samples.

Table 1 Agencies and their Drug Testing Laboratories

Laboratory

Agency

Immunoassay

Department o f the Air Force

Northwest Toxicology

Emit

Department o f the Army

Northwest Toxicology

Abuscreen RIA

Department o f Justice

PharmChem

Emit

Department o f the Navy

Navy

Abuscreen RIA
& Coat-a-Count RIA

Department o f Transportation

Laboratory Corporation of
America (previously.
CompuChem)

Department o f Veterans Affairs

Navy

90% KIMS, 10% EMIT
Additional TDx
amphetamines screen.
Abuscreen RIA
& Coat-A-Count RIA
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Cummulative screening data from six federal agencies for 1993 and 1994 is included
in Table 2. The table lists the total number o f federal civilian urine samples tested for
illegal drugs under HHS guidelines in 1993 and 1994, at the selected agencies. The
civilians were employed by the Departments o f Air Force, Army, Justice, Navy,
Transportation and Veterans Affairs. Table 2 also includes the number o f samples which
tested positive by the FDA approved screening immunoassay. Each of those samples were
submitted for confirmatory testing. The table also reflects the number of samples which
were then confirmed positive by GC/MS.
For example, during 1993 in the six agencies studied, 37,414 urine samples were tested
for amphetamines, 184 were screened positive by an FDA approved immunoassay and
submitted for confirmatory testing. One hundred forty three samples were ultimately confirmed
positive by GC/MS.

Table 2 Departments of A ir Force, Army, Justice, Navy, Transportation,
and Veterans Affairs Cummulative Screening Results •

Date
TOTALS
93
TOTALS
94

Positive Screened/ Positive Confirmations/ Total Screened
Amph
Benzoyl.
Opiates
PCP
THC
184/143/
37414
220/169/
37173

436/415/
48813
380/377/
45523

338/252/
34029
293/205/
33426

97/81/
33159
96/83/
32442

442/432/
48813
462/452/
45493

• All screening summaries include blind quality control/ proficiency samples.
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Calculations were made o f the overall confirmed positive rates for each o f the five
major drugs o f abuse (or metabolites) for 1993 and 1994, using the cummulative data
from Air Force, Army, Justice, Navy, Transportation and Veterans Affairs. (Table 2A).
This was calculated by dividing the number of confirmed positive samples by the total
number o f urine samples tested. In 1994 for instance, 1286 samples were confirmed
positive from the 45,523 urine samples tested- this generates a confirmed positive rate of
2.82%.

Table 2A
Cummulative federal agency
laboratory confirmed positive rates
(Departments of A ir Force, Army,
Justice, Navy, Transportation, VA)
Date
Positive
rate
2.71%
1993 overall
0.38%
Amphetamines
Benzoylecgonine 0.85%
Opiates
0.74%
0.24%
Phencyclidine
Marijuana (THC) 0.89%
2.82%
1994 overall
0.45%
Amphetamines
Benzoylecgonine 0.83%
Opiates
0.61%
0.26%
Phencyclidine
Marijuana (THC) 0.99%
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Table 2B compiles cummulative false positive rates for the six agencies, they are
0.356% and 0.362% for 1993 and 1994 respectively. It is calculated by subtracting the
number o f samples confirmed positive from the number screened positive and dividing this
by the total number o f samples screened. In 1993, there were 1497 positive screens, 1323
confirmed positive in a total o f 48813 urine tests (more samples were tested for THC and
benzoylecgonine than any other drug, thus the denominator will be that number). This
equates to a false positive rate of (1497-1323) / 48813 or 0.356%.

Table 2B
Cummulative federal agency false presumptive
positive rates (Departm ents of Air Force, Army,
Justice, Navy, Transportation,and Veterans Affairs)
Date

1993 overall
Amphetamines
Benzoylecgonine
Opiates
Phencyclidine
Marijuana (THC)
1994 overall
Amphetamines
Benzoylecgonine
Opiates
Phencyclidine
Marijuana (THC)

False
Presumptive
Positive Rate
0.356%
0.110%
0.043%
0.253%
0.043%
0.020%
0.362%
0.137%
0.007%
0.263%
0.040%
0.022%

95%
Confidence
Intervals
0.352-0.360%
0.107-0.113%
0.041-0.045%
0.248-0.258%
0.041-0.045%
0.019-0.021%
0.358-0.366%
0.133-0.141%
0.006-0.008%
0.258-0.268%
0.038-0.042%
0.021-0.023%

|
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Table 2C lists the cummulative Positive Predictive Value (or PPV) for the six agencies.
Positive Predictive Values are an important index in this study. It may be defined as the
likelihood that a positive test result from a screening test is indicative of a true positive.
(Glaser, 1995). Due to the variation between immunoassays many labs utilize data on
positive predictive values data when they select and purchase particular commercial
immunoassays. In this study true positives are assumed to be those samples which test
positive (at or above the threshold level) on the GC/MS confirmatory test. Marijuana
and Benzoylecgonine consistently showed the best PPV in the study.
Table 2C
Cummulative Positive Predictive
Value (PPV), (Departments A ir Force,
Army, Justice, Navy, Transportation,

Date
1993 overall
Amphetamines
Benzoylecgonine
Opiates
Phencyclidine
Marijuana (THC)
1994 overall
Amphetamines
Benzoylecgonine
Opiates
Phencyclidine
Marijuana (THC)

Positive
Predictive
Value
88.4%
77.7%
95.2%
74.6%
83.5%
97.7%
88.6%
76.8%
99.2%
70.0%
86.5%
97.8%

95%
Confidence
Intervals
88.1-88.7%
77.3-78.1%
95.0-95.4%
74.1-75.1%
83.1-83.9%
97.6-97.8%
88.3-88.9%
76.4-77.2%
99.1-99.3%
69.5-70.5%
86.1-86.9%
97.7-97.9%
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Tables 3, 4, 5, 6, 7, and 8 compiles the data submitted by each agency, they are:
Air Force (table 3), Army (table 4), Justice (table 5), Navy (table 6), Transportation (table 7),
and Veterans Affairs (table 8). The tables show the number o f agency urine samples tested,
the number screened positive for each drug and metabolite, and the corresponding number
confirmed positive.
In 1994 Northwest Toxicology which performed drug testing services for the Department
o f the Air Force (table 3), confirmed all 96 THC samples which screened positive by EMIT
immunoassay (see also Table 1).

Table 3 Departm ent of Air Force Screening Results •

Date
TOTALS
93
TOTALS
94

Pos. Screened/ Pos. Confirmations/ Total Screened
Amph
Benzoyl.
Opiates
PCP

THC

11/07/973

81/81/5553

07/05/351

03/03/344

96/96/5553

13/11/954

40/40/6098

03/03/303

02/02/303

93/93/6068

• All screening summaries include blind quality control/ proficiency samples.
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Confirmed positive rates were determined for each agency, and categorized for each
drug/metabolite tested by that agency during 1993 and 1994. This data is contained in
table 3 A (Air Force), 4A (Army), 5A (Justice), 6A (Navy), 7A (Transportation) and 8A
(Veterans Affairs). Tables 4A- 8A are included on later pages following the applicable
agency screening results. Confirmed positive rates are defined as the number of positive
samples analyzed by GC/MS to be at or above the threshold level, in the total number
screened. The threshold level is a predetermined cutoff level established by DHHS below
which samples are classified as negative. For example the threshold for marijuana
confirmation is 15ng/ml.
Table 3A for instance lists marijuana as having the highest confirmed rate of any o f the
drugs of abuse at the Department o f the Air Force (1.73% and 1.53% for 1993 and 1994).
Table 3A
A ir Force laboratory confirmed positive rates
Date

1993 overall
Amphetamines
Benzoylecgonine
Opiates
Phencyclidine
Marijuana (THC)
1994 overall
Amphetamines
Benzoylecgonine
Opiates
Phencyclidine
Marijuana (THC)

Confirmed
Positive
rate
3.46%
0.72%
1.46%
1.42%
0.85%
1.73%
2.44%
1.15%
0.66%
0.99%
0.66%
1.53%
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Tables 3B -8B describe the false presumptive positive rates for the Departments o f Air
Force (3B),Army (4B), Justice (5B), Navy (6B), Transportation (7B) and Veterans
Affairs (8B). Typically false positive rates (or false presumptive positives) are used to
assess the number o f samples which are identified as positive with the immunoassay screen
but are not positive with the GC/MS confirmatory test. This is one of the most commonly
used indexes in drug testing literature. Due the low prevalence of drug abuse among
federal civilian employees, false presumptive positive rates are quite low. The Department
o f Air Force false presumptive positive rate (table 3B) o f 0.03% for 1994 was the lowest
in the study.
Table 3B
A ir Force false presumptive positive rates
Date

1993 overall
Amphetamines
Benzoylecgonine
Opiates
Phencyclidine
Marijuana (THC)
1994 overall
Amphetamines
Benzoylecgonine
Opiates
Phencyclidine
Marijuana (THC)

False
Presumptive
Positive rate
0.108%
0.411%
0%
0.570%
0%
0%
0.033%
0.210%
0%
0%
0%
0%

95%
Confidence
Intervals *
0.100-0.116%
0.408-0.414%
N/A
0.520-0.620%
N/A
N/A
0.028-0.038%
0.184-0.236%
N/A
N/A
N/A
N/A

* Confidence intervals can not be derived with rates o f either 0 or 100%.
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As described earlier, the Positive Predictive Value indexes are perhaps the most
important statistic in this study. In addition to the cummulative PPVs presented in Table
2C, Positive Predictive Values were determined for each agency for 1993 and 1994 and
were determined for each drug/metabolite tested by that agency during the same time
frame. As evidenced by Air Force data in Table 3C below, PPVs were excellent for both
marijuana (100%) and benzoylecgonine (100%). This was also true o f the other agencies.
Table 3C
A ir Force Positive Predictive Value
PPV
Date
Positive
Predictive
Value
97.0%
1993 overall
63.6%
Amphetamines
Benzoylecgonine 100%
71.4%
Opiates
100%
Phencyclidine
Marijuana (THC) 100%
1994 overall
98.7%
84.6%
Amphetamines
Benzoylecgonine 100%
100%
Opiates
100%
Phencyclidine
Marijuana (THC) 100%

95%
Confidence
Intervals *
96.6-97.4%
60.6-66.6%
N/A
66.7-76.1%
N/A
N/A
98.4-99.0%
82.3-86.9%
N/A
N/A
N/A
N/A

* Confidence intervals can not be derived from rates of either 0 or 100%.
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Department o f the Army screening results are tabulated in table 4. It is notable that all
THC and benzoylecgonine screens were confirmed. Army submitted all o f its sample for
testing for THC and benzoylecgonine. Some categories (those other than random, it
appears) were tested also for amphetamines, phencyclidine and opiates. Drug testing
services were supplied for the Army by Northwest Toxicology using RIA. (see Table 1).

Table 4 Department of Army Screening Results •

Date

Pos. Screened/ Pos. Confirmations/ Total Screened
Amph
Benzoyl.
Opiates
PCP

TOTALS 93

19/19/6611

TOTALS 94

27/24/5194

133/133/
13430
139/139/
8400

38/29/3848

12/10/2985

28/18/2098

5/5/1114

THC
119/119/
13430
116/116/
8400

• All screening summaries include blind quality control/ proficiency samples.
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The Department o f Army confirmed positive rates are presented in table 4A. As might
be expected from the literature review, opiates closely follow cocaine and marijuana with
the third highest confirmed positive rates.

Table 4A
Army laboratory confirmed positive rates
Date

Positive
rate
1993 overall
2.31%
Amphetamines
0.29%
Benzoylecgonine 1.00%
Opiates
0.75%
Phencyclidine
0.34%
0.89%
Marijuana
(THC)
1994 overall
3.61%
Amphetamines
0.46%
Benzoylecgonine 1.65%
Opiates
0.86%
Phencyclidine
0.45%
Marijuana (THC) 1.38%
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Table 4B provides data on false presumptive positive rates for the Department o f
Army. To reiterate the rates are derived from subtracting the number o f positive
confirmatory tests from the number o f positive screens divided by the total number
screened. Army and Air Force had the lowest false presumptive positive rates in the
study.
Table 4B
Arm y false presumptive positive rates
Date

1993 overall
Amphetamines
Benzoylecgonine
Opiates
Phencyclidine
Marijuana (THC)
1994 overall
Amphetamines
Benzoylecgonine
Opiates
Phencyclidine
Marijuana (THC)

False
Presumptive
Positive rate
0.082%
0%
0%
0.233%
0.067%
0%
0.155%
0.058%
0%
0.48%
0%
0%

95%
Confidence
Intervals *
0.078-0.086%
N/A
N/A
0.223-0.243%
0.058-0.076%
N/A
0.147-0.163%
0.052-0.064%
N/A
0.46-0.50%
N/A
N/A

* Confidence intervals can not be derived from rates of either 0 or 100%.
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Table 4C lists Army positive predictive values for each drug/metabolite and overall
Army rates for 1993 and 1994. Marijuana had the highest PPV at 100%, opiates had the
lowest at 76.3% and 64.3%.

Table 4C
Army Positive Predictive Value
PPV
Date
Positive
Predictive
Value
96.6%
1993 overall
Amphetamines
100%
Benzoylecgonine 100%
Opiates
76.3%
Phencyclidine
83.3%
Marijuana (THC) 100%
95.9%
1994 overall
Amphetamines
88.8%
Benzoylecgonine 100%
Opiates
64.3%
Phencyclidine
100%
100%
Marijuana (THC)

95%
Confidece
Intervals *
96.3-96.9%
N/A
N/A
74.9-77.7%
82.0-84.6%
N/A
95.5-96.3%
87.9-89.7%
N/A
62.3-66.3%
N/A
N/A

* Confidence intervals can not be derived from rates of either 0 or 100%.
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Department o f Justice (DOJ) screening results are listed below in table 5. Justice
submitted all urine samples for the battery o f analyses including amphetamines, benzoylecgonine,
opiates, PCP, and THC (unlike the Army and Air Force, which authorized testing o f some
categories for only marijuana and cocaine). Testing for the Justice Department was performed
by PharmChem using an EMIT immunoassay screen.
In 1994, 2619 urine samples obtained from DOJ employees were tested. O f these 15 were
screened positive by the EMIT immunoassay for amphetamines, 5 were later confirmed positive
by the GC/MS confirmatory test.

Table 5

Date
TOTALS
93
TOTALS
94

Department of Justice Screening Results •
Pos. Screened/ Pos. Confirmations/ Total Screened
Amph
Benzoyl.
Opiates
PCP

THC

21/7/2067

11/10/2067

27/16/2067

08/07/2067

08/07/2067

15/05/2619

04/04/2619

23/15/2619

04/04/2619

12/12/2619

• All screening summaries include blind quality control/ proficiency samples.
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Department o f Justice confirmed positive rates are found in table 5A. This table is of
special interest because opiates had the highest confirmed positive rates o f any o f the
drugs o f abuse at DOJ in both 1993 and 1994.

Table 5A
DOJ laboratory confirmed positive rates
Date
1993 overall
Amphetamines
Benzoylecgonine
Opiates
Phencyclidine
Marijuana (THC)
1994 overall
Amphetamines
Benzoylecgonine
Opiates
Phencyclidine
Marijuana (THC)

Positive
rate
2.3%
0.34%
0.48%
0.77%
0.34%
0.34%
1.5%
0.19%
0.15%
0.56%
0.15%
0.46%
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Department o f Justice false presumptive positive rates are found in table 5B.
Amphetamines and opiates had the highest false presumptive positive rates o f any o f
the Department o f Justice's tested drugs o f abuse.

Table SB
DOJ false presumptive positive rates
Date

False
Presumptive
Positive rate
1.25%
0.68%
0.048%
0.435%
0.048%
0.048%
0.687%
0.38%
0.%
0.31%
0%

1993 overall
Amphetamines
Benzoylecgonine
Opiates
Phencyclidine
Marijuana (THC)
1994 overall
Amphetamines
Benzoylecgonine
Opiates
Phencyclidine
Marijuana (THC) 0%

95%
Confidence
Intervals *
1.11-1.39%
0.66-0.70%
0.039-0.057%
0.415-0.455%
0.039-0.057%
0.039-0.057%
0.667-0.707%
0.36-0.40%
N/A
0.29-0.33%
N/A
N/A

* Confidence intervals can not be derived from rates of 0% or 100%.
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Positive Predictive Values for DOJ are contained in table 5C. Amphetamines had a
PPV o f 33 1/3% for both 1993 and 1994. PharmChem which performed contract
drug testing services for the Department o f Justice reported use o f EMIT as its
immunoassay screen.

Table 5C
D O J Positive Predictive Value
PPV
Date
Positive
Predictive
Value
1993 overall
66.2%
Amphetamines
33.3%
Benzoylecgonine 90.9%
Opiates
59.3%
Phencyclidine
87.5%
Marijuana (THC) 92.3%
1994 overall
69.0%
Amphetamines
33.3%
Benzoylecgonine 100%
Opiates
65.2%
Phencyclidine
100%
Marijuana (THC) 100%

95%
Confidence
Intervals *
64.2-68.2%
31.3-35.3%
89.7-92.1%
57.2-61.4%
86.1-88.9%
91.2-93.4%
67.2-70.8%
31.5-35.1%
N/A
63.4-67.0%
N/A
N/A

* Confidence intervals can not be derived from rates o f either 0 or 100%.
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Table 6 lists screening data for the Department of the Navy. Navy civilian and military
analysts performed its own drugtesting services at its accredited labs in Norfolk, Va. and
Great Lakes, Illinois. Navy is unique among the drug testing laboratories in that it routinely
performs two RIA immunoassay screens. Table 6 is notable in the comparatively large
number of phencyclidine samples which screened and were ultimately confirmed positive.
For instance Navy labs found about 48 lab positive PCP samples in the two year period.

Table 6 Department of Navy Screening Results •

Date
TOTALS
93**
TOTALS
9 4 **

Pos. Screened/ Pos. Confirmations/ Total Screened
Amph
BenzoyL
Opiates
PCP
30/26/
11612
58/51/
13334

92/82/
11612
81/81/
13334

101/85/
11612
105/60/
13334

24/20/
11612
29/28/
13334

THC
84/80/
11612
120/115/
13334

• All screening summaries include blind quality control/ proficiency samples.
** Navy data was missing for January, February, 1993 and June 1994. Data was inserted
based on Navy monthly averages for 1993 and 1994 respectively.
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Table 6A found below, lists confirmed positive rates for the Department of the Navy in
1993 and 1994. Overall confirmed positive rates were consistent throughout the Navy in
1993 and 1994 at about 2.5%.

Table 6 A
Navy laboratory confirmed positive rates
Date

Positive
rate
1993 overall
2.52%
Amphetamines
0.22%
Benzoylecgonine 0.71%
0.73%
Opiates
0.17%
Phencyclidine
Marijuana (THC) 0.67%
1994 overall
2.51%
Amphetamines
0.38%
Benzoylecgonine 0.61%
0.45%
Opiates
Phencyclidine
0.21%
Marijuana (THC) 0.86%
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False presumptive positive rates for the Navy are contained in table 6B. Navy rates
(along with all the agencies in this study), are very low- and this in part may be attributed
to the low prevalence o f drug abuse among civilians.

Table 6B
Navy false presumptive positive rates
Date

False
Presumptive
Positive rate
0.327%
1993 overall
0.034%
Amphetamines
Benzoylecgonine 0.086%
Opiates
0.138%
Phencyclidine
0.034%
Marijuana (THC) 0.034%
1994 overall
0.435%
Amphetamines
0.052%
Benzoylecgonine 0%
Opiates
0.337%
0.007%
Phencyclidine
0.038%
Marijuana (THC)

95%
Confidence
Intervals *
0.319-0.335%
0.031-0.037%
0.081-0.091%
0.132-0.144%
0.032-0.36%
0.032-0.036%
0.427-0.443%
0.049-0.055%
N/A
0.329-0.345%
0.006-0.008%
0.035-0.041%

* Confidence intervals can not be derived from rates of either 0 or 100%.
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Table 6C lists Positive Predictive Values for the Navy. For in sta n c e the

1993

overall statistics

indicate that 88.5% of the Navy results obtained by the RIA screening immunoassay were
ultimately confirmed by G C /M S .
Table 6C
Navy Positive Predictive Value
PPV
Date
Positive
Predictive Value
1993 overall
Amphetamines
Benzoylecgonine
Opiates
Phencyclidine
Marijuana (THC)
1994 overall
Amphetamines
Benzoylecgonine
Opiates
Phencyclidine
Marijuana (THC)

88.5%
86.7%
89.1%
84.2%
83.3%
95.2%
85.2%
87.9%
100%
57.1%
96.6%
95.8%

95%
Confidence
Intervals
87.9-89.1%
86.1-87.3%
88.5-89.7%
83.5-84.9%
82.7-84.0%
94.8-95.6%
84.6-85.8%
87.3-88.5%
N/A
56.2-58.0%
96.3-96.9%
95.5-96.1%

* Confidence intervals can not be derived from rates o f either 0 or 100%.
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The most interesting agency results obtained in this study came from the Department
o f Transportation. Efforts were made by the researcher to ascertain the validity o f the
data supplied by Transportation (from Laboratory Corporation of America), including
seeking clarification from DOT on at least three separate occasions. Below in Table 7 is
a synopsis o f the data supplied by DOT regarding drug testing o f Transportation civilian
employees in 1993 and 1994.

Table 7 D epartm ent of Transportation Screening Results •

Date
TOTALS
93
TOTALS
94

Pos. Screened/ Pos. Confirmations/ Total Screened
Amph
Benzoyl.
Opiates
PCP
75/58/
11196
76/49/
10954

91/83/
11196
66/64/
10954

99/71/
11196
76/59/
10954

13/12/
11196
21/09/
10954

THC
72/70/
11196
65/61/
10954

• All screening summaries include blind quality control/proficiency samples.

Doctor Wingert o f the Laboratory Corporation of America reports that his lab
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Doctor Wingert o f the Laboratory Corporation o f America reports that his lab
utilized KIMs in approximately 90% o f the cases while EMIT was used in about 10%,
for the analysis o f DOT samples in 1993 and 1994. The Laboratory Corporation of
America also used a second immunoassay screen for positive amphetamine samples by
TDx. Table 2A lists the confirmed positive rates by the lab for DOT samples.

Table 7A
DOT laboratory confirmed positive rates
Date
1993 overall
Amphetamines
Benzoylecgonine
Opiates
Phencyclidine
Marijuana (THC)
1994 overall
Amphetamines
Benzoylecgonine
Opiates
Phencyclidine
Marijuana (THC)

Positive
rate
0.82%
0.01%
0.15%
0.59%
0%
0.07%
0.72%
0.02%
0.11%
0.50%
0%
0.11%
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Table 7B lists the false presumptive positive rates for the Department o f
Transportation in 1993 and 1994. False presumptive positives (or positive tests on
the screening immunoassay which subsequently test negative and beneath the threshold
level on the GC/MS confirmatory test) ranged from overall rates o f 0.500% in 1993 to
0.566% in 1994.

Table 7B
DO T false presumptive positive rates
Date

False
Presumptive
Positive rate
1993 overall
0.500%
Amphetamines
0.152%
Benzoylecgonine 0.071%
Opiates
0.250%
Phencyclidine
0.009%
Marijuana (THC) 0.018%
1994 overall
0.566%
0.246%
Amphetamines
Benzoylecgonine 0.018%
Opiates
0.156%
Phencyclidine
0.110%
Marijuana (THC) 0.037%

95%
Confidence
Intervals
0.491-0.509%
0.145-0.159%
0.066- 0.076%0.242-0.258%
0.007-0.011%
0.015-0.021%
0.557-0.575%
0.238-0.254%
0.016-0.020%
0.149-0.163%
0.104-0.116%
0.033-0.041%
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The Positive Predictive Values for screening immunoassays used in the analysis o f
DOT employees are listed in Table 7C. To reiterate Positive Predictive Value is defined
as the ability o f the screening test to accurately assess positive samples. The PCP results
with a PPV for 1994 at 42.9% (and a combined rate o f 61.8% for both years) may cause
concern to the laboratory and agency alike.

Table 7C
DOT Positive Predictive Value
PPV
Date
Positive
Predictive
Value
84.0%
1993 overall
77.3%
Amphetamines
Benzoylecgonine 91.2%
71.7%
Opiates
92.3%
Phencyclidine
Marijuana (THC) 97.2%
79.6%
1994 overall
64.5%
Amphetamines
Benzoylecgonine 97.0%
77.6%
Opiates
42.9%
Phencyclidine
Marijuana (THC) 93.8%

95%
Confidence
Intervals *
83.3-84.7%
76.5-78.1%
90.7-91.7%
70.9-72.5%
91.8-92.8%
96.9-97.5%
78.8-80.4%
63.6-65.4%
96.7-97.3%
76.8-78.4%
42.0-43.8%
93.3-94.3%

* Confidence intervals can not be derived from rates of either 0 or 100%.
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The Department o f Veterans Affairs also utilized the Department o f the Navy
drug screening laboratories during 1993 and 1994. A summary o f the data
obtained from Veterans Affairs is contained below in table 8. For instance in 1994,
31 samples were screened positive by the RIA immunoassays for amphetamines and 29 o f
those were subsequently confirmed. This data is found below in table 8.

Table 8 Department of Veterans Affairs Screening Results •

Date
TOTALS
93
TOTALS
94

Pos. Screened/ Pos. Confirmations/ Total Screened
Amph
Benzoyl.
Opiates
PCP

TH C

28/26/4955

50/46/4955

66/46/4955

37/29/4955

63/60/4955

31/29/4118

50/49/4118

58/50/4118

35/35/4118

56/55/4118

• All screening summaries include blind quality control/ proficiency samples.
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Table 8A lists the confirmed positive rates for the Department of Veterans Affairs
during 1993 and 1994. Veterans Affairs had the highest confirmed positive rates in the
study. In 1993, 4.2% o f the samples tested were confirmed positive, and in 1994 -5.3%.

Table 8A
Veterans Affairs laboratory confirmed positive rates
Date
1993 overall
Amphetamines
Benzoylecgonine
Opiates
Phencyclidine
Marijuana (THC)
1994 overall
Amphetamines
Benzoylecgonine
Opiates
Phencyclidine
Marijuana (THC)

Confirmed
Positive rate
4.18%
0.52%
0.93%
0.93%
0.59%
1.21%
5.3%
0.70%
1.19%
1.21%
0.85%
1.34%
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False positives (or false presumptive positives) are contained in table 8B for Veterans
Affairs. As with most o f the other agencies the false presumptive positive rates are quite
low.

Table 8B
Veterans Affairs false presumptive
positive rates
Date

1993 overall
Amphetamines
Benzoylecgonine
Opiates
Phencyclidine
Marijuana (THC)
1994 overall
Amphetamines
Benzoylecgonine
Opiates
Phencyclidine
Maijuana (THC)

False
Presumptive
Positive rate
0.747%
0.040%
0.081%
0.403%
0.161%
0.061%
0.291%
0.049%
0.024%
0.191%
Q.%

0.024%

95%
Confidence
Interval *
0.735-0.759%
0.035-0.045%
0.073-0.089%
0.389-0.417%
0.151-0.171%
0.054-0.068%
0.277-0.305%
0.042-0.056%
0.019-0.029
0.179-0.203%
N/A
0.019-0.029%

* Confidence intervals can not be derived from 0 or 100% rates.
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Table 8C contains data on Positive Predictive Values for Veterans Affairs in 1993 and
1994. In 1993 for example, Veterans Affairs RIA immunoassay screens predicted
actual laboratory positive test results in 84.8% o f the cases.

Table 8C
Veterans Affairs Positive Predictive Value
PPV
Date
Positive
95%
Predictive
Confidence
Value
Intervals*
1993 overall
84.8%
83.8-85.8%
Amphetamines
92.9%
92.2-93.6%
Benzoylecgonine 92.0%
91.2-92.8%
Opiates
69.7%
68.4-71.0%
Phencyclidine
78.4%
77.3-79.5%
94.6-95.8%
Marijuana (THC) 95.2%
1994 overall
94.8%
94.1-95.5%
Amphetamines
93.5%
92.7-94.3%
Benzoylecgonine 98.0%
97.6-98.4%
Opiates
86.2%
85.1-87.3%
100%
Phencyclidine
N/A
Marijuana (THC) 98.2%
97.8-98.6%
* Confidence intervals can not be derived fron rates of either 0 or 100%.
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Comparison o f positive immunoassays and positive GC/MS confirmatory tests.
Research Question #1
Research question #1 asks if there is a difference in the number o f positive
immunoassay screens and the number o f samples which tested positive on the
GC/MS confirmatory test. As evidenced by the screened positive rates and confirmed
positive rates found in table 9 below, there is in fact a difference between the number
and the rate for the two testing categories. This difference exists for all 5 categories
overall, and for each individual category o f drug/metabolite. Further information on
the differences which exist between the initial and confirmatory tests may be found in
both the positive predictive value and false presumptive positive rates o f the screening
test.
Table 9 Comparison of Screening positives and GC/MS positives (95% Confidence
Intervals), 1993 and 1994 combined results •
Screened
positive
rate

Confirm. PPV of
positive
screening test
rate

False
Presumptive
Positive Rate

Amphet.

nNumber
of
samples
74587

0.0054

0.0042

Benzoylec.

94336

0.0086

0.0084

Opiates

67455

0.0094

0.0068

PCP

65601

0.0029

0.0025

THC

94306

0.0096

0.0094

All 5 Drugs
Cummul.

94336

0.03125

0.0277

0.123%
(0.121-0.125%)
0.022%
(0.021-0.23%)
0.258%
0.255-0.261%
0.044%
(0.042 -0.046%)
0.021%
0.020 -0.022%)
0.359%
(0.356%-0.362%)

Drug/
Metabolites

77.2%
(76.9-77.5%)
97.4%
(97.1-97.5%)
72.4%
(72.1%-72.7%)
85.0%
(84.7-85.3%)
97.8%
(97.7-97.9%)
88.5%
(88.3-88.7%)

• All screening summaries include blind quality control/proficiency samples.
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Research Question #2
The second research question dealt with which drug/ metabolite showed the greatest
difference between the positive test results o f the immunoassay and the positive GC/MS
results. The best method o f evaluation for this second research question is the positive
predictive value. Positive predictive values measure the likelihood that the positive
screening test is accurate- and the identified illegal drug is in fact present in the
urine sample.
Table 2C (pg. 53) and Table 9 (pg. 78) lists the positive predictive value for opiates
(74.6% and 70.0% for 1993 and 1994, the combined rate for both years is 72.4%). The
next largest difference was found for amphetamines (77.7% and 76.8% for 1993 and 1994
respectively). Marijuana (THC) had the highest overall positive predictive value o f any o f
the drugs o f abuse (97.8%), followed closely by cocaine metabolite (97.4%).
Comparisons were also made between immunoassays. Which immunoassays had the
highest PPV for each drug? Which had the highest overall PPV for all five drugs
combined? Which was the lowest? Table 10, below lists the screening results by
immunoassay- it provides information on the number of samples tested, the number
screened positive, and confirmed positive. Both the positive predictive values and false
presumptive positive rates were derived fiom those results. EMIT screening data was
used by the Departments o f Air Force and Justice. RIA data was used by Army, Navy and
Veterans Affairs. The Department o f Transportation lab used KIMs as the major
immunoassay.
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KIMS was reportedly used by Laboratory Corporation o f America for DOT samples
(for the purpose o f this comparison all DOT samples are attributed to KIMs, even
though the lab said it used EMIT 10% of the time). (Personal communication, 5/96). It is
also important to recognize that Navy labs utilized two screening RIA's for the testing o f
its own Navy and Veterans Affairs samples.

Table 10 Comparison of Screening Results by Immunoassay, 1993 and 1994 •
N um ber o f Positive samples Screened/Pos. Confirmed/ Total Screened
Benzoylec.
Immuno Amphet.
Opiates
PCP
THC

All S Drugs

EM IT

60/30/6613

136/135/
16337

60/39/5340

17/16/5333

209/208/
16307

482/428/
16337

RIA

193/175/
45824

545/530/
55849

396/288/
39965

142/127/
38118

558/545/
55849

1834/1665/
55849

KIMS

151/107/
22150

157/147/
22150

175/130/
22150

34/21/
22150

137/131/
22150

654/536/
22150

• All screening summaries include blind quality control/ proficiency samples.
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Table 10A below lists positive predictive values for each o f the three immunoassays
studied. Calculations were made for each drug/metabolite tested and data accumulated
for all five drugs. While Table 9 presented earlier (pg. 78) showed that amphetamines had
the second lowest positive predictive value found in this study at 77.2%, as indicated here
radioimmunoassay is by far the most accurate immunoassay for the detection o f
amphetamines. In fact even assuming the low end o f the 95% confidence interval, RIA
successfully identified more than 90% of amphetamine samples. While KIMs detected
70.9% o f positive amphetamine samples correctly, it is important to consider the second
immunoassay screen used by Lab Corp. o f America by FPIA.
RIA had higher overall positive predictive values and detected slightly more positive
samples than EMIT. However it is inappropriate to use this study as a validation o f RIA
over EMIT since the data supplied by Navy labs showed use o f two RIA screens, while all
data supplied by labs which used EMIT, indicated the use o f the lone immunoassay.
Data for KIMs shows lower positive predictive values than either other FDA approved
immunoassay. Particularly for phencyclidine samples, these results may indicate
laboratory problems, questionable lab quality control, and are inconsistent with results for
KIMs published in the literature. There was evidence in the literature however that KIMs
experienced problems early in it use, and these results were obtained for 1993 and 1994,
only a year after the technology was introduced.
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Table 10A Comparison of Positive Predictive Values for Different Immunoassays •
Positive Predictive Value (95% Confidence Intervals), 1993 and 1994 Combined
All 5
PCP
Benzoyle. Opiates
THC
Immuno Amphet.
Drugs
99.3%
65.0%
94.1%
99.5%
88.8%
50.0%
EM IT
(63.7(48.8(99.2(93.5(99.4(88.399.4%)
66.3%)
94.7%)
99.6%)
51.2%)
89.3%)
RIA

90.7%
(90.491.0%)

97.2%
(97.197.3%)

72.7%
(72.373.1%)

89.4%
(89.189.7%)

97.6%
(97.597.7%)

90.7%
(90.591.1%)

KIMS

70.9%
(70.371.5%)

93.6%
(93.393.9%)

74.3%
(73.774.9%)

61.8%
(61.262.4%)

95.6%
(95.395.9%)

82.0%
(81.582.5%)

• All screening summaries include blind quality control/ proficiency samples.
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For the average employee, false positive rates may be the most important statistic in any
study dealing with drug testing methodology. Similarly they help us to at least estimate
the specificity o f a specific technique as it compares to another technique or instrument.
Table 10B lists false presumptive positive rates for each o f the immunoassays. In the
event that the guidelines were revised and labs were authorized to use only an
immunoassay screen to detect illegal drug use, the 0.532% false presumptive positive rate
found by KIMs immunoassay would result in more than 370 false positive federal civilian
test results per year. (*This estimate assumes that labs only use KIMs, results o f this study
are accurate, and that testing continues at the current rate o f approximately 70,000
employees per year). Even if other FDA approved immunoassay technology is utilized
however, failure to confirm positive test results with the "gold standard" GC/MS would
result in false positive test results for at best 209 employees per year (using low
confidence interval for RIA).
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Table 10B Comparison of False Presumptive Positive Rates by Immunoassay •
Immunoassay False Presumptive Positive Rates (95% Confidence Intervals)
PCP
All 5
Benzoyle. Opiates
THC
Immuno. A m phet
Drugs
0.006%
0.39%
0.019%
0.006%
0.331%
0.454%
EM IT
(0.018(0.005(0.38(0.324(0.005(0.4520.40%)
0.007%)
0.020%)
0.007%)
0.338%)
0.456%)
RIA

0.039%
(0.0370.041%)

0.027%
(0.0260.028%)

0.271%
(0.2680.274%)

0.039%
(0.0370.041%)

0.023%
(0.0220.024%)

0.303%
(0.2990.307%)

KIMS

0.199%
(0.1940.204%)

0.045%
(0.0420.048%)

0.203%
(0.1980.208%)

0.059%
(0.0560.062%)

0.027%
(0.0250.029%

0.532%
(0.5250.539%)

• All screening summaries include blind quality control/ proficiency samples.
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Chapter V
SUMMARY, CONCLUSIONS, AND RECOMMENDATIONS
The following chapter summarizes the findings and recommendations from this study.
The chapter covers the following areas in order: summary, interpretation and implications,
conclusions and recommendations.
Summary
The purpose of this study was to find under the same analytical conditions whether a
difference exists between the number o f positive test results from the screening
immunoassay and positive GC/MS confirmatory results of urine samples tested for drugs
o f abuse.
Analytical conditions were fixed, thus eliminating several potential confounding
variables. Only federal agencies following DHHS mandatory drugtesting guidelines were
utilized. These agencies used the same DHHS approved collection procedures, as well as
accredited laboratories. The study covered the time period from January 1993- December
1994.
Whether differences existed between positive screening and confirmatory tests was
measured by comparing positive predictive values and false presumptive positive rates for
each o f the five drugs/ metabolites.
Confidence intervals were established at 95% for each estimate/calculation performed.
This means that the researcher is confident to within 95% that the true estimate lies within
the range listed. There is only a 5% possibility that the true estimate lies outside the range
listed.
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The six federal agencies performing the largest amount o f drug testing during 1993 and
1994 were chosen to participate in this study. It is estimated that the study results
utilizing data from the Departments of Transportation, Navy, Army, Air Force, Justice and
Veterans Affairs, covered more than 50% o f the federal civilian employees tested in 1993
and 1994.
Interpretation and Implication
The study shows that indeed a difference does exist between the results of the
screening and confirmatory tests. This answers the underlying question of the studyimmunoassay technology has not improved to such an extent that GC/MS confirmation
is unnecessary- quite the contrary.
It was expected due to previous studies/ literature that the analyses of amphetamines
and perhaps opiates would show significant differences between the results o f the
screening and confirmatory tests. (Although much of literature regarding opiates
was more relevant to verification of illicit use of opiates by the MRO rather than
erroneous screening results). A significant difference was not expected for each
drug/ metabolite, nor as evidenced by the data in table 9 (pg. 78) did this occur. Clearly
the major problems arise from opiates, amphetamines and PCP. Screening immunoassays
for benzoylecgonine and THC are quite accurate- yet none o f the immunoassays detected
100% o f either metabolite.
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As the study progressed many additional questions arose - such as what effect did the
Navy1s use o f a second RIA immunoassay have on their results? Was the positive
predictive value o f their screening dramatically improved by the use o f this second RIA
prior to confirmatory testing?
It may be assumed the second RIA test would have an impact by eliminating
from confirmatory testing those samples which may have been contaminated, had
carryover problem following a positive cocaine result, or encountered some sort o f other
random error. The Navy's use of a second RIA appeared quite logical, and cost effective
by eliminating further expensive confirmatory testing- those samples which tested negative
on the second RIA. Yet, when compared to the Army's results which according to
Northwest Toxicology uses a lone RIA prior to confirmatory testing, Navy had a lower
positive predictive value for nearly every drug (Tables 4C, 6C).
The Role of the Medical Review Officer
The SAMHSA semiannual surveys covering October 1, 1992 through March 31, 1994
reported the total number o f federal civilian employees with urine samples which were
verified positive for phencyclidine as 8. This study which covered approximately the same
time period, and examined about half of the federal employees tested found more than 82
PCP laboratory confirmed positives per year (table 2, page 50). This is a substantial
difference, PCP unlike the other drugs of abuse is not prescribed as a medication, nor
contained in over the counter medications or foods. Simply, PCP's presence in urine has
no medical justification (MacDonald, 1990).
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One assumes PCP laboratory confirmed positives were not verified by Medical
Review Officers because o f chain o f custody, laboratory quality control or other
procedural problems.
The last three SAMHS A surveys indicate verified positive test rates o f about 0.6%,
this study found laboratory confirmed rates o f 2.7-2.8%. While it is important to
recognize that the laboratory confirmed positive rates derived from this study are inflated
because it includes mandatory proficiency samples, there exists nonetheless a substantial
difference between laboratory confirmed positive rates and verified positive rates.
Clearly the Medical Review Officers are playing a critical role in agency drug free
workplace programs, as evidenced by overall statistics and those regarding PCP.
Conclusions and Recommendations
It is perhaps even incumbent upon employees and employers alike to recognize that
yes poppy seeds may cause positive opiate results and not just the screening tests. Federal
agencies have not been immune to significant breaches from DHHS requirements,
particularly Departments o f Interior, Transportation, and Navy. (Department o f Interior,
Inspector General, (1992); U.S. General Accounting Office, 1989, GAO/GGD-89-80;
DeRochi, 1995).
For agency officials (or for private industry personnel) who direct drug testing
programs, the immunoassay utilized by the laboratory may affect the number and type of
samples submitted for confirmatory testing- and the employers ultimate cost.
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In only a very few instances did it appear that the monthly statistical summaries had not
been faxed or transmitted from the lab to the agency solely as a result of the FOIA
request. Agencies need to review these monthly summaries, not just because someone
initiated a FOIA request to access them but because they provide valuable information on
the state o f drug testing at the agency.
One o f the purposes o f this thesis was to look at how drug testing actually works in the
government and overall it appears to be working well. Clearly the confirmatory test
continues to play an important role and to be necessary to obtain accurate laboratory
results. GAO has not recommended eliminating confirmatory tests for civilian employees,
nor based on the results o f this study would such a recommendation be merited.
Practical Implications From This Study
1. The Health and Human Services mandate to perform confirmatory testing on
all positive urine samples is an appropriate one. Any efforts to reduce costs o f federal
testing programs should not be directed at limiting the use of GC/MS confirmatory
testing.
2. Private companies who fail to use GC/MS confirmatory testing are liable for
significant legal consequences. This study shows that failure to use confirmatory testing
by GC/MS cannot be scientifically supported.
3. Both federal and private industry might well opt to use the immunoassays found in
this study and other studies cited earlier, which provide the best positive predictive value.
Utilization of appropriate immunoassays could reduce federal drug testing costs.
4. Federal agencies should utilize data provided by their contract laboratories and
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SAMHSA to make decisions on their drug free workplace programs. Agencies need to
take an active role in assuring that state o f the art technology and knowledge is utilized in
the analysis of agency drug testing samples.
5.

Due to the limited number o f phencyclidine samples which have been verified by

MRO's (<0.01%), federal agencies may wish to emulate Departments of Air Force and
Army and test for phencyclidine in only rare instances. This should also reduce costs.
This topic and why PCP was verified in such a small percentage o f cases is recommended
for further study.
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